


***TET2* lesions enhance the aggressiveness of *CEBPA*-mutant acute myeloid leukemia by rebalancing *GATA2* expression**

Received: 2 November 2022

Accepted: 22 September 2023

Published online: 04 October 2023

 Check for updates

Elizabeth Heyes^{1,10}, Anna S. Wilhelmson^{2,3,4,10}, Anne Wenzel^{2,3,4}, Gabriele Manhart¹, Thomas Eder¹, Mikkel B. Schuster^{2,3,4}, Edwin Rzepa¹, Sachin Pundhir^{2,3,4}, Teresa D'Altri^{2,3,4}, Anne-Katrine Frank^{2,3,4}, Coline Gentil^{2,3,4}, Jakob Woessmann⁵, Erwin M. Schoof⁵, Manja Meggendorfer⁶, Jürg Schwaller⁷, Torsten Haferlach⁶, Florian Grebien^{1,8,11}✉ & Bo T. Porse^{2,3,4,9,11}✉

The myeloid transcription factor *CEBPA* is recurrently biallelically mutated (i.e., double mutated; *CEBPA*^{DM}) in acute myeloid leukemia (AML) with a combination of hypermorphic N-terminal mutations (*CEBPA*^{NT}), promoting expression of the leukemia-associated p30 isoform, and amorphic C-terminal mutations. The most frequently co-mutated genes in *CEBPA*^{DM} AML are *GATA2* and *TET2*, however the molecular mechanisms underlying this co-mutational spectrum are incomplete. By combining transcriptomic and epigenomic analyses of *CEBPA-TET2* co-mutated patients with models thereof, we identify *GATA2* as a conserved target of the *CEBPA-TET2* mutational axis, providing a rationale for the mutational spectra in *CEBPA*^{DM} AML. Elevated *CEBPA* levels, driven by *CEBPA*^{NT}, mediate recruitment of *TET2* to the *Gata2* distal hematopoietic enhancer thereby increasing *Gata2* expression. Concurrent loss of *TET2* in *CEBPA*^{DM} AML induces a competitive advantage by increasing *Gata2* promoter methylation, thereby rebalancing *GATA2* levels. Of clinical relevance, demethylating treatment of *Cebpa-Tet2* co-mutated AML restores *Gata2* levels and prolongs disease latency.

Acute myeloid leukemia (AML) is characterized by genetic alterations affecting the proliferation and/or differentiation of hematopoietic stem or progenitor cells (HSPCs). Thereby, the expansion of immature myeloid precursors, at the expense of normal hematopoiesis, ultimately leads to bone marrow (BM) failure if left untreated. Recent sequencing efforts have identified numerous recurrent mutations in AML and revealed patterns of mutational co-segregation, suggesting

that synergism between certain lesions drives leukemogenesis¹. While we now recognize these patterns, the mechanistic basis for context-specific positive or negative selection of certain lesions remains to be elucidated in most cases.

CCAAT enhancer binding protein alpha (*CEBPA*) is a hematopoietic lineage-specific transcription factor that binds and primes genes for myeloid development and is required for differentiation and

¹University of Veterinary Medicine, Institute of Medical Biochemistry, Vienna, Austria. ²The Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. ³Biotech Research and Innovation Centre (BRIC), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. ⁴Danish Stem Cell Center (DanStem), Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark. ⁵Department of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark. ⁶MLL Munich Leukemia Laboratory, Munich, Germany. ⁷Department of Biomedicine, University Children's Hospital Basel, Basel, Switzerland. ⁸St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria. ⁹Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. ¹⁰These authors contributed equally: Elizabeth Heyes, Anna S. Wilhelmson. ¹¹These authors jointly supervised this work: Florian Grebien, Bo T. Porse. ✉e-mail: Florian.Grebien@vetmeduni.ac.at; bo.porse@finsenlab.dk

maturation of granulocytes². The gene encoding CEBPA is biallelically mutated (i.e., double mutated; *CEBPA*^{DM}) in 3–15% of de novo AML patients^{3–9}. *CEBPA*^{DM} patients harbor either biallelic N-terminal mutations or a combination of a monoallelic N-terminal mutation together with a C-terminal mutation in the other allele. Whereas N-terminal CEBPA (*CEBPA*^{NT}) lesions promote the expression of the truncated p30 isoform, C-terminal mutations result in CEBPA variants that are unable to dimerize or bind DNA, thus rendering them inactive. Hence, CEBPA p30 homodimers are the sole entity with functional transcription factor activity in *CEBPA*^{DM} AML. This is in contrast to normal hematopoietic cells where the full-length p42 isoform is predominantly expressed². CEBPA p30 lacks two of three transactivation elements present in p42, but retains one transcriptional activating element and the basic-region leucine-zipper, which enables dimerization and DNA-binding¹⁰. CEBPA p30 has functions distinct from CEBPA p42 and can bind an isoform-specific set of enhancers and regulate the expression of downstream effector genes, such as *Nt5e* and *Msi2*^{11,12}. Importantly, in the context of *CEBPA*^{DM} AML, the *CEBPA*^{NT} is hypermorphic, leading to higher levels of the transcription factor, and thus, increased binding to enhancers and subsequent deregulation of gene expression¹¹. In line with these data, mice with CEBPA p30 expression driven from the endogenous *Cebpa* locus develop AML with full penetrance within a year¹³.

Most patients with *CEBPA*^{DM} AML also feature additional mutations in *GATA2*, *TET2*, *WT1*, *NRAS*, *FLT3*, or *CSF3R*⁹. Several of these mutations are found together with *CEBPA*^{DM} more frequently than expected by the individual frequency of each mutation, while other combinations are statistically underrepresented. Recent studies have shed light on the molecular mechanisms underlying mutational cooperativity for some of the co-mutated genes, i.e. *GATA2*¹⁴ and *CSF3R*¹⁵, while mechanistic insight is still lacking for other subgroups of *CEBPA*^{DM} AML. Of particular importance are mutations in the gene encoding the methylcytosine dioxygenase *TET2* which, by converting 5-methylcytosine to 5-hydroxymethylcytosine, promotes DNA demethylation. *TET2* mutations (*TET2*^{MUT}) are frequent in *CEBPA*^{DM} AML cases and are associated with inferior prognosis^{16,17}. Moreover, loss of *Tet2* has been implicated in accelerating and/or aggravating hematological malignancies in combination with several other recurrent gain-of-function and loss-of-function mutations^{18–20}, reflecting the importance of appropriately regulated DNA demethylation in normal hematopoiesis. Importantly, while *Tet2* loss alone only mildly affects hematopoiesis with myeloid skewing and increased competitiveness of HSCs¹⁸, as well as the increased propensity of leukemic blasts to switch to a more stem-like phenotype²¹, it does not induce overt leukemia per se^{22–24}. Despite being extensively studied, mechanistic insights of how *TET2* loss-of-function cooperates with other aberrations have been hampered by the fact that malignant cells have been compared to their normal, wild-type counterparts in many studies.

In the present work, we sought to overcome this limitation by comparing *CEBPA*-mutant AML in the presence and absence of additional mutations in *TET2*. By combining transcriptomic and epigenomic analyses of relevant *in vitro* and *in vivo* models as well as data from AML patients, we identified an intricate mechanism where *TET2* loss-of-function rebalances *Gata2* expression levels in *Cebpa*^{DM} AML, and hence drives an aggressive disease.

Results

TET2 mutations impair outcome for patients with *CEBPA*-mutant AML

To validate previous reports on the spectrum of co-occurring mutations in *CEBPA*^{DM} AML patients, we compiled data from 557 *CEBPA*^{DM} cases and evaluated the co-occurrence of other known leukemia driver mutations^{3–7,17}. *TET2* was the second most frequently co-mutated gene, with 1 in 5 *CEBPA*^{DM} cases harboring *TET2* mutations (Fig. 1a; Supplemental Table 1). Importantly, the survival of *TET2*-mutant (*TET2*^{MUT})




Fig. 1 | *TET2* mutations impair outcome for patients with *CEBPA*-mutant AML. **a** Frequency of co-occurring mutations in *CEBPA*^{DM} AML cases, data aggregated from published cohorts^{3–8,17} (321–557 cases; detailed in Supplemental Table 1). **b** Overall survival of *CEBPA*^{DM} patients with wild-type (*TET2*^{WT}; 84 patients) or mutated *TET2* (*TET2*^{MUT}; 35 patients). The data were analyzed by Mantel-Cox Log-rank test. **c** Volcano plot depicting differentially expressed genes dependent on *TET2* mutational status in the cohort of *CEBPA*-mutant patients in the Beat AML dataset (*TET2*^{WT} 11 and *TET2*^{MUT} 5 patients). Differential analysis was performed with DESeq2 ($P < 0.05$). Source data are provided as a Source Data file.

CEBPA^{DM} patients was significantly lower than *TET2* wild-type (*TET2*^{WT}) *CEBPA*^{DM} patients (Fig. 1b), consistent with previous reports¹⁶, while the presence of *TET2* mutations did not cause a higher overall number of mutations in *CEBPA*^{DM} patients (Supplemental Fig. 1a).

To investigate the functional consequences of *TET2* and *CEBPA* co-mutations, we analyzed RNA sequencing (RNA-seq) data from the Beat AML dataset¹. We identified 1546 up- and 1201 downregulated genes in patients harboring a combination of *CEBPA* and *TET2* mutations when compared to *CEBPA*-mutant patients with wild-type *TET2* (Fig. 1c). Similarly, a slight overrepresentation of up-regulated genes was observed when comparing *CEBPA*^{WT}*TET2*^{MUT} patients to *CEBPA*^{WT}*TET2*^{WT} patients (601 up- and 527 downregulated). In line with the lower overall survival of *TET2*^{MUT}*CEBPA*^{DM} patients, pathways related to inflammation, hypoxia, and aggressive cancer were upregulated

in *CEBPA-TET2* co-mutated patients (Supplemental Fig. 1b). The overrepresentation of up-regulated genes associated with TET2 deficiency in *CEBPA^{MUT}* (and *CEBPA^{WT}*) patients is somewhat surprising, as increased DNA methylation upon TET2 loss would be expected to cause global transcriptional repression. However, other co-occurring mutations and residual DNA demethylase activity from the *TET2^{WT}* allele may cause a more complex pattern of gene expression.

These findings indicate that mutations in *TET2* enhance the aggressiveness of *CEBPA*-mutant AML by deregulation of critical cellular pathways.

TET2 deficiency accelerates *Cebpa*-mutant AML

To study the effect of *TET2* mutations in *CEBPA^{DM}* AML in pathophysiologically relevant *in vitro* and *in vivo* models, we utilized cell and murine models in which expression of the p30 isoform is retained (*Cebpa^{p30/p30}* or *Cebpa^{Δ/p30}*), while the normal p42 isoform of CEBPA is completely lost¹³. Since *TET2* is predominantly inactivated by loss-of-function mutations²⁵, we modeled *TET2* mutations either by the introduction of mutations with the CRISPR-Cas9 technology or by conditional knockout of the *Tet2* alleles.

First, we introduced *Tet2* mutations into a murine myeloid progenitor cell model (*Cebpa^{p30/p30}*) (Fig. 2a). *Tet2*-targeted cells displayed a selective advantage, as they outcompeted *Cebpa^{p30/p30}* cells (Fig. 2b). Detailed analysis of the *Tet2* mutation that was associated with the proliferative advantage showed that the *Tet2* locus had acquired a +1 insertion in exon 3, which resulted in a downstream premature termination codon (Supplemental Fig. 2a, b). In line with this, clones isolated from the targeted cell pool exhibited strongly reduced TET2 protein expression (Supplemental Fig. 2c). Gene expression analysis revealed that *Tet2* loss in *Cebpa^{p30/p30}* cells caused downregulated expression of 916 genes, while only 540 genes were upregulated (Fig. 2c). Gene set enrichment analysis (GSEA) showed higher expression of MYC and E2F targets in *Cebpa^{p30/p30} Tet2*-mutated cells, consistent with their proliferative advantage (Supplemental Fig. 2d).

In summary, these data show that CRISPR/Cas9-induced TET2 loss provides a competitive advantage to myeloid progenitors expressing the oncogenic CEBPA variant p30.

Next, we wanted to assess the impact of hematopoietic expression of CEBPA p30 (*Cebpa^{Δ/p30}*) with TET2-deficiency (*Tet2^{-/-}*) on AML initiation *in vivo*. To do so, we transplanted lethally irradiated recipient mice with BM cells derived from mice with relevant allele combinations and, following hematopoietic reconstitution, induced hematopoietic-specific knockout of the *Cebpa* WT allele and/or the *Tet2* alleles (Fig. 2d). The combination of CEBPA p30 expression with *Tet2* loss led to an early expansion of myeloid (Mac1⁺) cells in the BM and blood compared to mice with hematopoietic cells featuring either alteration on its own (Fig. 2e; Supplemental Fig. 2e). Conforming to patient data and data obtained from *Cebpa^{p30/p30}* cells, *Cebpa^{Δ/p30}Tet2^{Δ/Δ}* hematopoietic cells gave rise to AML with shorter latency than *Cebpa^{Δ/p30}Tet2^{+/+}* cells, with a median survival of 23 and 43 weeks, respectively (Fig. 2f). Mice transplanted with *Cebpa^{Δ/p30}Tet2^{+/+}* BM cells developed leukemia with similar latency as mice transplanted with *Cebpa^{p30/p30}* fetal liver cells¹³. This is consistent with the matching expression of *Cebpa* in these two contexts (1.1 ± 0.24 vs. 1.0 ± 0.13 (relative expression) in *Cebpa^{p30/p30}* and *Cebpa^{Δ/p30}Tet2^{+/+}* AML blasts *n* = 3/group, respectively). TET2 deficiency alone (*Cebpa^{Δ/+}Tet2^{Δ/Δ}*) did not give rise to AML and cells which retained expression of the p42 isoform from one allele (*Cebpa^{+/p30}*) only sporadically underwent leukemic transformation, in line with unaltered *Cebpa* expression levels in these cells (Fig. 2f; Supplemental Fig. 2f; 1.03 ± 0.14 vs. 1.0 ± 0.04 (relative expression) in *Cebpa^{Δ/p30}* and *Cebpa^{Δ/+}* cells *n* = 2–3/group, respectively). The transformed blasts expressed myeloid (Mac1⁺) and granulocytic (Gr1⁺) markers, confirming the myeloid origin of the leukemia (Supplemental Fig. 2g). The leukemias were transplantable into secondary recipients, and the shorter latency of the TET2-deficient *Cebpa^{DM}* AML was

preserved in this setting (Supplemental Fig. 2h–i), indicating that TET2 not only has important tumor suppressive functions during malignant transformation but also during progression of AML.

We performed RNA-seq on *Cebpa^{Δ/p30}* (*Tet2* WT and knockout) AML blasts to assess changes in gene expression upon TET2 deficiency. Again, we found that the majority of differentially expressed genes was decreased in TET2-deficient AML blasts, with 176 down- vs. 58 up-regulated genes (Fig. 2g). GSEA highlighted upregulation of genes involved in IL-6-JAK-STAT-signaling and hypoxia, in line with RNA-seq data from human *TET2^{MUT}CEBPA^{MUT}* cases (Supplemental Fig. 1b; Supplemental Fig. 2j). Furthermore, pathways related to cell cycle progression (G2M checkpoint and E2F targets) were enriched in TET2-deficient AML, indicating increased growth upon loss of TET2, consistent with the effects observed in the cell model (Supplemental Fig. 2d; Supplemental Fig. 2j). In line with this, we found that a higher frequency of *Cebpa^{Δ/p30}Tet2^{Δ/Δ}* blasts expressed the proliferation marker Ki67 (Fig. 2h). In addition, we also observed increased proliferative capacity of *Cebpa^{Δ/p30}Tet2^{Δ/Δ}* blasts compared to *Cebpa^{Δ/p30}Tet2^{+/+}* blasts *ex vivo*. This difference was dependent on *Tet2* status, as the TET2 cofactor Vitamin C was able to mitigate proliferation of *Cebpa^{Δ/p30}Tet2^{+/+}* but not of *Cebpa^{Δ/p30}Tet2^{Δ/Δ}* cells (Supplemental Fig. 2k).

Collectively, these data show that TET2 deficiency accelerates the establishment and progression of CEBPA p30-driven AML *in vivo*.

Loss of TET2 leads to reduced *Gata2* levels in *Cebpa*-mutant AML

To find conserved gene targets of the CEBPA-TET2 axis, we integrated the transcriptomic data from our *in vitro* and *in vivo* models with gene expression analyses from AML patients harboring *CEBPA* and *TET2* mutations. Three target genes exhibited downregulated expression in all three data sets; *FUT8*, *GATA2*, and *SIRT5* (Fig. 3a; Supplemental Fig. 3a–c).

Since the deregulation of these three genes was observed across species and differential experimental setups, we next aimed to investigate if their decreased gene expression was a direct result of TET2 deficiency. We therefore assessed chromatin accessibility and DNA methylation as a proxy for TET2 binding and activity²⁶. Through assay for transposase-accessible chromatin sequencing (ATAC-seq), we identified 1809 differentially accessible regions in *Cebpa^{p30/p30}Tet2^{MUT}* vs. *Cebpa^{p30/p30}Tet2^{WT}* cells, and consistent with an activating effect of TET2, the majority of differential regions were less accessible in TET2-deficient cells (Fig. 3b). Half of the ATAC-seq peaks downregulated upon *Tet2* mutation were located in promoters, and these regions were enriched for GATA and NFAT motifs (Fig. 3c; Supplemental Fig. 3d). Using whole genome bisulfite sequencing (WGBS), we observed a global increase in DNA methylation in *Cebpa^{Δ/p30}Tet2^{Δ/Δ}* vs. *Cebpa^{Δ/p30}Tet2^{+/+}* AML blasts, consistent with a loss of demethylase activity in *Tet2* knockout blasts (Fig. 3d). Increased DNA methylation was observed in promoter regions of genes whose expression were downregulated upon TET2 loss (+54%; Fig. 3e), while upregulated and not differently expressed genes did not show any marked changes. Strikingly, this pattern was not apparent when DNA methylation was evaluated across gene bodies (Supplemental Fig. 3e). Non-expressed genes exhibited equal increase in DNA methylation across promoters and gene bodies (Fig. 3e; Supplemental Fig. 3e). Since increased gene body methylation is not associated with gene repression²⁷, we evaluated whether a gain in gene body methylation was coupled to a gain in promoter methylation for the down-regulated genes. In the presence of promoter hypermethylation, the bodies of down-regulated genes were more prevalently hypermethylated compared to neutral and up-regulated genes (34.8% [95%CI 18.8–55.11] vs. 18.1% [16.4–19.9], *p* = 0.0427). While, in the absence of promoter hypermethylation, the bodies of up-regulated genes tended to be hypermethylated compared to neutral and down-regulated genes (13.8% [95%CI 7.2–24.9] vs. 7.1% [6.8–7.4], *p* = 0.0518). Thus, loss of TET2 in *Cebpa^{DM}* cells caused decreased chromatin accessibility and increased methylation of DNA in promoters of TET2-responsive genes,




Fig. 2 | TET2 deficiency accelerates *Cebpa*-mutant AML. **a** Schematic representation of generation of *Tet2*-knockout clones with CRISPR/Cas9. The illustration was created with BioRender.com. **b** Proliferative outgrowth of *Cebpa*^{Δp30} cells with *Tet2* indels. **c** Volcano plot depicting differentially expressed genes dependent on the *Tet2* mutational status in *Cebpa*^{Δp30} cells (*Tet2*^{WT} 7 and *Tet2*^{MUT} 5 clones). Differential analysis was performed with DESeq2 ($P < 0.05$). **d** Experimental setup for evaluating the effect of *Tet2*-deficiency (*Tet2*^{Δ/Δ}) in *Cebpa*^{Δp30} AML initiation in vivo. The illustration was created with BioRender.com. **e** Myeloid (Mac1⁺) contribution of donor-derived blood and bone marrow (BM) cells evaluated after BM transplantation and Cre-LoxP recombination. (Blood samples: Week 12; 6 mice per group. Week 24; *Cebpa*^{Δp30}*Tet2*^{+/+} and *Cebpa*^{+/Δ}*Tet2*^{Δ/Δ} 6 mice per group and *Cebpa*^{+/Δ}*Tet2*^{Δ/Δ} 3 mice. Week 36; 3 mice per group. BM

samples: 3 mice per group.) Data are presented as mean ± SEM and analyzed by one-way-ANOVA followed by Dunnett's multiple comparisons correction. **f** Survival of lethally irradiated recipient mice after BM transplantation and Cre-LoxP recombination (*Cebpa*^{Δp30}*Tet2*^{+/+} 12 mice, *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} 14 mice, and *Cebpa*^{+/Δ}*Tet2*^{Δ/Δ} 14 mice). The data were analyzed by Mantel-Cox Log-rank test. **g** Volcano plot depicting differentially expressed genes dependent on *Tet2* deficiency status in *Cebpa*^{Δp30} leukemic blasts (samples from 3 mice per group). Differential analysis was performed with DESeq2 ($P < 0.05$). **h** Frequency of proliferating (Ki67⁺) cells in BM of moribund recipient mice (specimens from 3 mice per group). Data are presented as mean ± SEM and analyzed by a two-tailed unpaired *t*-test. Source data are provided as a Source Data file.

consistent with previous reports showing that TET2 binding is enriched in promoters of TET2-regulated genes²⁸.

To identify direct CEBPA-TET2 gene target(s), we evaluated the previously identified conserved candidates based on changes in DNA methylation of their promoters. Out of the three target genes, only the gene encoding the transcription factor GATA-binding factor 2 (GATA2) showed a gain of DNA methylation in the promoter of the gene variant 2 (*Gata2* V2) upon TET2 deficiency (+46%; Fig. 3f). In line with this,

specifically the *Gata2* V2 mRNA isoform was downregulated in TET2-deficient *Cebpa*^{Δp30} AML blasts (−86%; Fig. 3g), while changes in mRNA expression and promoter methylation of *Gata2* V1 did not reach statistical significance (Fig. 3f, g).

In summary, these analyses identify *Gata2* (locus overview in Fig. 3h) as a conserved target of the CEBPA-TET2 axis across several settings. TET2 deficiency causes increased DNA methylation of the *Gata2* promoter, resulting in reduced mRNA expression.




Fig. 3 | Loss of TET2 leads to reduced *Gata2* levels in *Cebpa*-mutant AML. **a** Conserved targets of the CEBPA-TET2 axis visualized in a Venn-diagram of downregulated genes in *CEBPA*-*TET2* co-mutated AML overlaid with corresponding data from *Tet2*-deficient in vivo and in vitro models of *Cebpa*^{DM} AML ($P = 0.0264$ vs. number of overlapping genes expected by random distribution assessed by Wilson/Brown binomial test). **b** Heatmap of differentially accessible regions assessed by assay for transposase-accessible chromatin sequencing (ATAC-seq; FDR < 0.05), and **c** genomic distribution of downregulated peaks (FDR < 0.05, Log2FC < 0) upon *Tet2* mutation (4 clones per group). Differential analysis was performed with DiffBind and region enrichment analysis with GREAT. **d** Representative genome wide DNA-methylation status in leukemic blasts from the in vivo model assessed by whole genome bisulfite sequencing (WGBS) showing frequency of methyl-cytosine (mC) across the transcription start site (TSS) ± 1000 base pairs, gene body scaled to 4000 base pairs, and transcription termination site (TES) ± 1000 base pairs. Methylation analysis was performed with Bismark and visualized using deepTools.


e Median and interquartile range of percent mC at promoters of down- ($n = 172$), not expressed ($n = 6539$), not differentially expressed (not DE; $n = 14759$) and up-regulated ($n = 57$) genes (averaged data generated from 2 *Cebpa*^{Δ/p30}*Tet2*^{+/+} and 3 *Cebpa*^{Δ/p30}*Tet2*^{Δ/Δ} mice). Whiskers indicates max–min and data were analyzed by two-tailed unpaired *t*-test. **f** Promoter DNA methylation of conserved target genes in leukemic blast (samples from 2 *Cebpa*^{Δ/p30}*Tet2*^{+/+} and 3 *Cebpa*^{Δ/p30}*Tet2*^{Δ/Δ} mice). Data are presented as mean \pm SEM. The data were log-transformed and analyzed by two-tailed unpaired *t*-test. **g** *Gata2* variant mRNA expression in *Cebpa*^{Δ/p30}*Tet2*^{Δ/Δ} and *Cebpa*^{Δ/p30}*Tet2*^{+/+} leukemic blasts (samples from 3 mice per group). Data are presented as mean \pm SEM. The data were log-transformed and analyzed by a two-tailed unpaired *t*-test. **h** Schematic genomic view of the *Gata2* locus, including representative examples of assay for transposase-accessible chromatin using sequencing (ATAC-seq) in *Cebpa*^{p30/p30} cells. Source data are provided as a Source Data file.

Moderate *Gata2* reduction increases competitiveness of *Cebpa*-mutant AML

GATA2 is an essential transcription factor for hematopoietic cells and has profound effects on HSC maintenance. Moreover, it is recurrently mutated in AML^{29,30} and GATA2 lesions are overrepresented in *CEBPA*^{DM} AML^{8,16,31–33}. Given these critical roles of GATA2, we next examined the consequences of reduced GATA2 levels in *CEBPA*^{DM} AML.

To test if reduced *Gata2* expression would provide a competitive advantage in vivo, we set up an RNA-interference (RNAi) based competition assay (Fig. 4a) utilizing established *Cebpa*^{p30/p30} leukemia cells, in which both *Cebpa* (+56–73%) and *Gata2* (+45–56%) levels are increased modestly compared to primary *Cebpa*^{Δ/p30}*Tet2*^{+/+} blasts^{11,34}. First, we identified four short hairpin RNAs (shRNA) which lowered *Gata2* expression to a varying degree (Fig. 4b). Upon transplantation of

shRNA-expressing cells, we observed a non-monotonic relationship between *Gata2* expression levels and competitiveness, as measured by sh*Gata2*-to-shControl ratios. While efficient downregulation of *Gata2* expression did not provide any competitive advantage to *Cebpa*^{DM} cells, moderate silencing imposed a three-fold increase in their ability to compete (Fig. 4c, d). Repetition of this experiment including only the most and least efficient shRNAs in a separate experiment yielded similar results (Supplemental Fig. 4a, b). These results were mirrored by increased expression of the proliferation marker *Ki67* in cells expressing the least efficient *Gata2*-targeting shRNA but not the most efficient one (Supplemental Fig. 4c). To test if the same effects are observed in an in vitro setting, we targeted *Gata2* in *Cebpa*^{p30/p30} cells using the CRISPR/Cas9 approach. *Gata2*-targeted cells showed a proliferative advantage over *Gata2*^{WT} cells, leading to their outgrowth



(Fig. 4e, f). In accordance with previously published data that complete loss of *Gata2* expression results in a loss of competitiveness^{35–37}, we found that only clones with heterozygous *Gata2* inactivation were viable, while clones with homozygous mutations in *Gata2* could not be recovered (Supplemental Fig. 4d).

If the pro-leukemogenic effect of *TET2* mutations was, at least partly, caused by lowering *GATA2* expression, we reasoned that

concomitant mutations in both genes would be redundant and thus, the pattern of *TET2* and *GATA2* mutations would be mutually exclusive. Indeed, *TET2*^{MUT}*CEBPA*^{DM} AML cases showed a lower frequency of *GATA2* mutations than expected from the frequency of *GATA2* mutations in *TET2*^{WT}*CEBPA*^{DM} AML cases (Fig. 4g; Supplemental Table 2a), which was also true for all AML cases (3.5% in *TET2*^{MUT} vs. 8.9% in *TET2*^{WT}; Supplemental Fig. 4e; Supplemental Table 2b). Importantly,

Fig. 4 | Moderate *Gata2* reduction increases competitiveness of *Cebpa*-mutant AML. **a** Experimental setup for evaluating the effect of *Gata2* knockdown, via short hairpin RNA (shRNA) mediated silencing, on *Cebpa*^{p30/p30} leukemic cells in a competitive in vivo assay. The illustration was created with BioRender.com. **b** *Gata2* mRNA in *Cebpa*^{p30/p30} leukemic cells prior to transplantation. **c** Representative flow cytometry profiles of input and output of shControl (no knockdown), sh*Gata2A* (low knockdown), and sh*Gata2D* (high knockdown). **d** Competitive advantage of targeting shRNA (GFP⁺) vs. non-targeting shRNA (YFP⁺) cells in vivo assessed as by flow cytometry (Control 4, sh*Gata2A* 4, sh*Gata2B* 4, sh*Gata2C* 4, and sh*Gata2D* 3 mice). Data are presented as mean±SEM. Data were log-transformed and analyzed by one-way-ANOVA followed by Dunnett's multiple comparisons correction.

whereas mutations in *WT1* followed the same pattern as *TET2*, *CSF3R* mutations appeared in equal frequency between *TET2*^{MUT}*CEBPA*^{DM} and *TET2*^{WT}*CEBPA*^{DM} AML cases, and *ASXL1* mutations were increased in *TET2*^{MUT}*CEBPA*^{DM} AML (Supplemental Fig. 4f; Supplemental Table 2c–e). While we favor a functional redundancy model, we cannot exclude that co-mutation of *TET2* and *GATA2* could induce synthetic lethality in AML cells, as *Gata2*-loss has been shown to induce terminal myeloid differentiation³⁷.

Altogether, our data suggest that loss of *TET2* in *Cebpa*^{DM} AML causes a moderate decrease in *Gata2* expression, which in turn increases the competitive fitness of the leukemia. Hence, this indicates that *TET2* and *GATA2* mutations are partially redundant in *CEBPA*^{DM} AML, providing a mechanistic rationale for the mutational spectrum observed in this AML entity.

Increased *CEBPA* p30 binding to the *Gata2* distal hematopoietic enhancer drives expression of *Gata2* via *TET2*

We next asked if *GATA2* expression is dependent on *CEBPA* mutational status. To this end, we exploited published transcriptomics data from human and mouse *CEBPA*^{DM} AML¹¹. *GATA2* expression was increased in human *CEBPA*^{DM} leukemic granulocyte/monocyte progenitors (GMPs) compared to GMPs from healthy donors (+77%; Supplemental Fig. 5a). Correspondingly, *Gata2* was upregulated in murine *Cebpa*^{p30/p30} leukemic GMPs as compared to normal GMPs (+43%; Fig. 5a). Likewise, analysis of AML patient data from the BEAT AML study¹, revealed that both *CEBPA* and *GATA2* expression were increased in *CEBPA*^{NT} AML compared to *CEBPA*^{WT} AML (+91% and +37%, respectively), while *GATA2* expression was reverted to *CEBPA*^{WT} level in *CEBPA*^{NT}*TET2*^{MUT} AML (Supplemental Fig. 5b, c). Since *CEBPA* is known to exert its transcription factor activity by binding to enhancers and thereby promote gene expression³⁸, we assessed the binding of *CEBPA* to the crucial *Gata2* distal hematopoietic enhancer (*G2DHE*; -77 kb in mouse) that governs *Gata2* expression in hematopoietic stem and progenitor cells including GMPs^{11,39}. Notably, we found substantially increased levels of *CEBPA* bound to the *G2DHE* in *Cebpa*^{p30/p30} leukemic GMPs compared to their normal counterparts (+147%; Fig. 5b), while the binding levels associated with other known proximal and distal *cis*-regulatory elements of the *Gata2* gene were unchanged (Supplemental Fig. 5d, e). Additionally, *TET2* showed significant binding to the *G2DHE* in *Cebpa*^{p30/p30} cells (Fig. 5c). However, DNA methylation at the *G2DHE* was low and unaltered upon *Tet2* loss (Supplemental Fig. 5f). Importantly, *CEBPA* binding, as assessed by ChIP-qPCR, was not altered by introduction of *Tet2* mutations in *Cebpa*^{p30/p30} cells (Supplemental Fig. 5g).

These results prompted us to test if *CEBPA* binding to the *G2DHE* modulates *Gata2* expression in *Cebpa*^{DM} AML. We deleted 250–500 bp fragments of the *Gata2* enhancer encompassing the *CEBPA* binding site using the CRISPR/Cas9 approach in *Cebpa*^{p30/p30} cells in vitro. Expression of total *Gata2* mRNA, as well as both individual transcript variants, was decreased upon targeting the genomic region with strong *CEBPA* binding compared

to non-targeting control (Fig. 5c–e, Supplemental Fig. 5h–k). In contrast, *Gata2* expression was unchanged when *G2DHE* deletions were introduced in *Cebpa*^{p30/p30}*Tet2*^{MUT} cells (Supplemental Fig. 5l, m). Combined, these data suggest that *CEBPA* binding to the *G2DHE* is important for promoting *Gata2* expression in *Cebpa*^{DM} AML. Further, the *G2DHE* has been shown to primarily regulate expression of the hematopoietic specific *Gata2* variant 2 (*V2*)^{40,41}, conforming with our data that particularly the *Gata2* *V2* promoter displayed an increase in DNA methylation and that the *Gata2* *V2* mRNA was downregulated in *TET2*-deficient *Cebpa*^{DM} AML blasts (Fig. 3f–g).

Next, we tested if the reduction of *CEBPA* in AML cells influenced the expression and promoter DNA methylation of *Gata2* *V2*. Given the dependence of *CEBPA*^{DM} AML on *CEBPA* for survival and maintenance, we utilized MLL-fusion-driven AML, in which *CEBPA* is dispensable for the maintenance of established leukemia⁴². Cre-mediated loss of *Cebpa* in leukemic cells expressing the inducible MLL-AF9 fusion-protein (*iMLL-AF9*⁺*Cebpa*^{Δb}; Fig. 5f) caused reduced *Gata2* *V2* mRNA levels compared to control cells (*iMLL-AF9*⁺*Cebpa*^{fl/fl}) (-72%; Fig. 5g). Importantly, the methylation frequency of the CpG island located at the *Gata2* *V2* promoter was increased in two separate leukemic lines (+186%; Fig. 5h; Supplemental Fig. 5n), suggesting that *Gata2* *V2* mRNA expression is regulated via the *CEBPA*-*TET2* axis. Finally, we assessed *TET2* binding to the *G2DHE* upon *Cebpa* knockdown in *Cebpa*^{p30/p30} cells using ChIP-qPCR (Fig. 5i). Notably, we observed decreased *TET2* binding to the *G2DHE* in cells expressing sh*Cebpa* compared to cells expressing control shRNA, verifying that *CEBPA* is important for recruitment of *TET2* to the *G2DHE* (Fig. 5j).

In light of these findings, we asked whether elevated *CEBPA* level and not the *CEBPA* mutation(s) per se, drives the selective pressure for *GATA2* and/or *TET2* loss in AML to achieve moderate *GATA2* levels that are optimal for leukemia growth. We therefore stratified AML cases in the Beat AML cohort¹ based on *CEBPA* expression and assessed their *GATA2* and *TET2* mutational status. Indeed, the frequency of *GATA2* and/or *TET2* mutations was three-fold higher in *CEBPA*^{HIGH} AML compared to the *CEBPA*^{LOW} samples (Fig. 5k). In line with previous data showing a hypermorphic effect of *CEBPA*^{DM}¹¹, the *CEBPA*^{HIGH} group contained the majority of the *CEBPA*-mutant cases in the cohort (82 and 100% of *CEBPA*SM and *CEBPA*^{DM}, respectively), while none of the cases in the *CEBPA*^{LOW} group were *CEBPA*-mutated.

In conclusion, our data show that elevated *CEBPA* binding to the *G2DHE*, driven by the hypermorphic effect of *Cebpa*^{NT}, increases *TET2*-mediated demethylation of the *Gata2* promoter, which leads to elevated *Gata2* levels in *Cebpa*^{DM} AML. In this context, *Cebpa*^{DM} AML cells gain a competitive advantage by loss of *TET2*, which in turn promotes an increase in DNA methylation at the *Gata2* promoter resulting in the rebalancing of *Gata2* levels.

Demethylating treatment restores *Gata2* expression and prolongs survival in *TET2*-deficient *Cebpa*-mutant AML

Finally, we investigated if treatment with the demethylating agent 5-azacytidine (5-AZA) would be beneficial in *TET2*-deficient *CEBPA*^{DM} AML. Ex vivo treatment with 5-AZA restored *Gata2* expression in




Fig. 5 | Increased CEBPA p30 binding to the *Gata2* distal hematopoietic enhancer drives expression of *Gata2* via TET2. **a** *Gata2* mRNA expression in mouse *Cebpa*^{p30/p30} leukemic granulocyte/monocyte progenitors (GMPs) vs normal GMPs (samples from 4 *Cebpa*^{+/+} and 2 *Cebpa*^{p30/p30} mice) and, **b** CEBPA binding to the *Gata2* distal hematopoietic enhancer (*G2DHE*; -77 kb) region (samples from 2 mice per group), data from Jakobsen et al.¹¹. Data are presented as mean ± SEM. Differential analysis was performed with DESeq2 ($P < 0.05$). **c** Schematic genomic view of the *Gata2* distal hematopoietic enhancer (*G2DHE*), including normalized chromatin immunoprecipitation sequencing (ChIP-seq) signal of CEBPA (data from Heyes et al.¹³), TET2 and H3K27Ac (data from Heyes et al.¹³), as well as assay for transposase-accessible chromatin using sequencing (ATAC-seq) in *Cebpa*^{p30/p30} cells without (light blue) and with (green) mutation in *Tet2*. **d** *Gata2* mRNA levels in response to targeting of the *G2DHE* by CRISPR-Cas9 in *Cebpa*^{p30/p30} cells in vitro using indicated sgRNAs and **e** the averaged change in *Gata2* mRNA levels of the 12 deletions (averaged data from 2 separate experiments). Data are presented as median ± range and analyzed by two-tailed Wilcoxon signed-rank test. **f** Experimental setup for evaluating the effects of *Cebpa* knockout on *Gata2* V2 mRNA expression and DNA methylation of the CpG island at the promoter of *Gata2*

V2 in MLL-fusion driven AML (*iMLL-AF9*). The illustration was created with BioRender.com. **g** *Gata2* V2 mRNA expression (leukemic cell lines generated from 2 separate mice were assayed on 2 separate days in 2–3 technical replicates each). Data are presented as mean ± SEM and the individual cell lines are indicated by circles or squares. Data were log-transformed and analyzed by two-tailed unpaired *t*-test. **h** DNA methylation of the *Gata2* V2 promoter CpG-island (2 separate leukemic cell lines). Data are presented as median ± range and the individual cell lines are indicated by circles or squares. **i** Experimental setup for evaluating the effects of *Cebpa* knockdown on TET2 binding to the *G2DHE* in *Cebpa*^{p30/p30} cells with inducible expression of shRNA targeting *Cebpa* and control (*Renilla*), respectively. The illustration was created with BioRender.com. **j** TET2 binding to the *G2DHE* assessed by ChIP-qPCR (3 replicates per condition). Data are presented as mean ± SEM and analyzed by two-tailed unpaired *t*-test. **k** Frequency of *GATA2* and/or *TET2* mutations (*GATA2*^{MUT} and *TET2*^{MUT}, respectively) in *CEBPA* high expressing (*CEBPA*^{HIGH}; 45 cases) vs. *CEBPA* low expressing (*CEBPA*^{LOW}; 61 cases) AML cases, data from Beat AML cohort¹. The distributions of *GATA2*^{MUT}/*TET2*^{WT} vs. *GATA2*^{MUT} and/or *TET2*^{MUT} cases were analyzed by Wilson/Brown binomial test. Source data are provided as a Source Data file.

Cebpa^{Δp30}*Tet2*^{Δ/Δ} blasts to levels observed in *Cebpa*^{Δp30}*Tet2*^{+/+}, while 5-AZA treatment did not affect *Gata2* levels in *Cebpa*^{Δp30}*Tet2*^{+/+} cells (Supplemental Fig. 6a). Moreover, 5-AZA decreased the viability of blasts from both genotypes, although to a higher degree in the TET2-deficient setting (-82% and -40%, respectively, $p < 0.01$; Supplemental Fig. 6b).

To evaluate if the enhanced effect of 5-AZA treatment in TET2-deficient AML would also hold true in vivo, mice were transplanted with *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} or *Cebpa*^{Δp30}*Tet2*^{+/+} AML blasts and treated with 5-AZA for three consecutive days after disease establishment (Fig. 6a). While the blast frequency of TET2-deficient *Cebpa*^{Δp30} AML decreased upon 5-AZA treatment (-62%; Fig. 6b), the treatment did not significantly decrease the frequency of TET2-proficient cells. Furthermore, 5-AZA treatment restored *Gata2* levels in *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} blasts in vivo to the same level as in *Cebpa*^{Δp30}*Tet2*^{+/+} blasts (Fig. 6c). Intriguingly, two out of three individual *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} leukemic clones (A + B) responded to 5-AZA treatment with a pronounced increase of *Gata2* levels and concomitant reduction of myeloid blasts, while one clone (C) appeared partially refractory to 5-AZA treatment, with limited increase of *Gata2* and no reduction of leukemic burden (Fig. 6b, c). Importantly, a longer intermittent 5-AZA treatment prolonged the survival of mice transplanted with *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} blasts from one of the responding clones (A) (median survival +22%; Fig. 6d, e), while it did not affect disease latency of mice transplanted with *Cebpa*^{Δp30}*Tet2*^{+/+} blasts (A).

In summary, we show that the demethylating agent 5-AZA can restore *Gata2* expression levels in TET2-deficient *Cebpa*^{DM} AML to that of TET2-proficient *Cebpa*^{DM} AML, and concomitantly reduce leukemic burden and prolong survival of mice transplanted with TET2-deficient *Cebpa*^{DM} leukemic blasts.

Discussion

Mutational cooperativity is a fundamental driver of cancer development, progression, and aggressiveness. For *CEBPA*^{DM} AML, co-occurring lesions have been found in genes such as *GATA2*, *TET2*, *WT1*, *FLT3*, and *CSFR3*. While the mechanistic basis for the cooperation between *CEBPA* and *GATA2/CSFR3* mutations has been investigated using mouse models^{14,15}, we have very little insight into why other lesions, such as those in *TET2*, are overrepresented in *CEBPA*^{DM} AML. Here, we show that TET2 loss-of-function in *CEBPA*^{DM} AML leads to an aggressive disease phenotype by rebalancing the increased and sub-optimal levels of *GATA2* that are induced by hypermorphic *CEBPA*^{NT} mutations driving *CEBPA*-p30 isoform expression (see model in Fig. 7a). Specifically, loss of TET2 binding to the hematopoietic-specific *G2DHE* enhancer results in increased DNA methylation in the promoter region of the hematopoietic-specific *Gata2* isoform (*Gata2* V2). This

proleukemic effect of TET2 loss can be reversed by the demethylating agent 5-AZA, suggesting that this could be a potential treatment option in *CEBPA*^{DM}*TET2*^{MUT} patients. Altogether, our work proposes that *CEBPA*-mutant AMLs acquire additional lesions in genes such as *GATA2* and *TET2* to reestablish balanced *GATA2* levels that permit leukemia development and progression.

Our work highlights the central importance of *GATA2* regulation in *CEBPA*-mutant AML. Specifically, we show that *GATA2* is a conserved target gene of *CEBPA* and *TET2*. Furthermore, the elevated levels of the *CEBPA* p30 variant likely mediate *GATA2* upregulation in *CEBPA*-mutant AML. The increased expression of *Gata2* is counteracted by loss of *TET2* in vitro and in vivo models of *Cebpa*^{DM} AML as well as in *CEBPA*/*TET2* co-mutated patients. This is accompanied by the gain of *Gata2* promoter DNA methylation. These findings are consistent with previous data showing that *Gata2* expression is TET2-dependent, as *Gata2* was downregulated in various *Tet2* knockout settings and that forced expression of *Gata2* decreased the competitiveness of both normal and malignant TET2-deficient cells^{28,43–45}. Further paralleling our data, TET2 deficiency in the context of *Fli3*^{ITD} AML has been shown to accelerate leukemia by hypermethylation and consequent silencing of the *Gata2* locus⁴³.

Strikingly, we found that while moderate reduction of *Gata2* expression increased competitiveness in *Cebpa*^{DM} AML both in vivo and in vitro, leukemia cells remain critically dependent on residual *GATA2* function. Indeed, homozygous *Gata2* lesions induced a strong inhibitory effect on *Cebpa*^{DM} AML in vitro³⁷, which was also observed in other AML subtypes as well as in normal hematopoietic stem cells^{36,46–48}. These findings are corroborated by a substantial body of genetic evidence supporting the importance of *GATA2* regulation in *CEBPA*-mutant AML. First, heterozygous *GATA2* lesions frequently co-occur with *CEBPA*^{DM} 4,8,16,17,31–33,49–52. Secondly, *GATA2* allele-specific expression is strongly associated with *CEBPA*^{DM} AML and is neither found in AML with reduced *CEBPA* expression (i.e. t(8;21)) nor in *CEBPA*-silenced AML⁵³. Thirdly, *TET2*^{MUT} and *GATA2*^{MUT} rarely co-occur in *CEBPA*^{DM} AML. Finally, we showed that mutations in *GATA2* and *TET2* are overrepresented in AML cases with high *CEBPA* expression. This supports the notion that unfavorable, high *GATA2* levels in AML promoted by the *CEBPA*-*TET2* axis are not limited to *CEBPA*^{DM} AML, but also include cases where *CEBPA* expression is high for other reasons. Further, this model also suggests that a major proleukemic effect of TET2 deficiency is to rebalance *GATA2* levels in the context of *CEBPA*^{DM} AML (see Fig. 7b).

GATA2 expression is mainly driven by the conserved *G2DHE* in normal myeloid progenitors and leukemic blasts by promoting expression from the hematopoietic specific *Gata2* V2 promoter^{39,40,44,54}. Our data demonstrate that *CEBPA* plays a key role in




Fig. 6 | Demethylating treatment restores *Gata2* expression and prolongs survival in TET2-deficient *Cebpa*-mutant AML. **a** Experimental setup for evaluating the effect of short-term 5-azacytidine (5-AZA) treatment in vivo. Recipient mice were sub-lethally irradiated and transplanted with leukemic BM from moribund secondary recipient mice. Three individual *Cebpa*^{Δp30}*Tet2*^{+/+} clones (A-C) and two *Cebpa*^{Δp30}*Tet2*^{Δ/Δ} clones (A-B) were used, respectively. The illustration was created with BioRender.com. **b** Expansion of myeloid (Mac1⁺) donor-derived cells in bone marrow (BM) assessed by flow cytometry, and **c** *Gata2* mRNA expression in sorted leukemic blasts by qPCR assessed 24 hours after the last of three injections of 5-AZA or vehicle (samples from 3 mice per clone and 6 and 9 mice per group, for

Cebpa^{Δp30}*Tet2*^{+/+} and *Cebpa*^{Δp30}*Tet2*^{Δ/Δ}, respectively). Dot plots showing individual mice for separate clones and bar graphs shows mean ± SEM for each group. Data were analyzed by Kruskal–Wallis test followed by Dunn’s correction for multiple comparisons. **d** Experimental setup for evaluating the effect of 5-AZA treatment on AML progression in vivo. The illustration was created with BioRender.com. **e** Survival of sub-lethally irradiated tertiary recipient mice after transplantation of leukemic BM from moribund secondary recipient mice (clone A from both genotypes) in response to intermittent 5-AZA treatment (5-AZA treated groups 8 mice and vehicle-treated groups 4 mice). The data were analyzed by Mantel–Cox Log-rank test. Source data are provided as a Source Data file.

regulating G2DHE activity. Specifically, we showed that the hypermorphic effects of *CEBPA*^{DM11}, and experimental models thereof, resulted in increased *GATA2* expression compared to *CEBPA*^{WT}, and that *CEBPA* deficiency resulted in reduced *Gata2* levels. Secondly, we observed increased *CEBPA* binding to the *G2DHE* in *Cebpa*^{DM} AML compared to normal progenitors and found that deletion or mutagenesis of the *CEBPA*-bound region of the enhancer resulted in lower expression of *Gata2* in *Cebpa*^{DM} cells. In further support of the role of *CEBPA*, the *G2DHE* is highly active in *CEBPA*^{DM} AML, with both elevated eRNA expression and levels of H3K27ac⁵³. An equally important role for *CEBPA* is observed in the context of *inv(3)* and *t(3;3)* AML in which inversions, translocations, and rearrangements involving the *EVII* gene at the *MECOM* locus, lead to hijacking of the *G2DHE* to promote *EVII* expression at the expense of *GATA2* expression thus resulting in *GATA2* haploinsufficiency^{55–58}. Here, *EVII* expression was found to be down-regulated following knockdown of *CEBPA* in *inv(3)* AML cells, and mutation of the *CEBPA* binding site in the hijacked enhancer reduced enhancer activity⁵⁸. In this context, *CEBPA*^{MUT} would not be favorable, and these lesions are indeed underrepresented in *inv(3)* and *t(3;3)* AML^{59–61}.

We hypothesized that *CEBPA* recruits *TET2* and thus mediates DNA demethylation of the *Gata2* V2 promoter in a *CEBPA*- and *TET2*-dependent manner. Indeed, we observed reduced *TET2*-binding to the *G2DHE* upon knockdown of *Cebpa* in *Cebpa*^{p30/p30} cells. Furthermore, *Gata2* V2 levels were decreased, and *Gata2* V2 promoter DNA methylation was increased upon *Cebpa* depletion in an MLL-AF9 leukemic setting where *CEBPA* is dispensable for maintenance of the leukemia. The concept of *CEBPA* as a recruiting factor for *TET2* is also supported by previous findings showing that both the p30 and p42 isoforms of *CEBPA* interact with *TET2* via the DNA binding domain of *CEBPA*^{62,63}.

Further, *CEBPA* binds preferentially to methylated DNA^{62,64}, and has been classified as a binding site-directed DNA demethylation-inducing transcription factor^{62,65}. Interestingly, *TET2* binds genomic regions that are enriched for *CEBP* motifs in myeloid cells, particularly in myeloid enhancers such as the *G2DHE*^{26,62}. Moreover, knockdown or knockout of *Tet2* leads to impaired upregulation of myeloid-specific genes upon *Cebpa* induction, with corresponding increased promoter methylation⁶⁶. Also, in *TET2*^{MUT} or *Tet2*^{-/-} leukemia an enrichment of *CEBP* motifs at or near hypermethylated CpGs was observed^{26,67}. Importantly, AML with silenced *CEBPA* is associated with DNA hypermethylation, a feature that is not present in *CEBPA*^{DM} AML, which may suggest a broader function of *CEBPA* in the recruitment of *TET2*⁶⁸. In summary, we conclude that *CEBPA* plays an important role in the recruitment of *TET2* to chromatin at the *G2DHE*, promoting DNA demethylation at the *Gata2* V2 promoter and the induction of *Gata2* expression. The extent to which this can be extended to other loci warrants further analysis but is supported by the data mentioned above.

While our findings suggest that *GATA2*^{MUT} and *TET2*^{MUT} both converge at rebalancing the increased expression of *GATA2* in *CEBPA*^{DM} AML, patients with *CEBPA*^{DM} and *GATA2*^{MUT} have a more favorable prognosis^{16,31–33,49} than patients harboring the *CEBPA*^{DM} and *TET2*^{MUT} combination^{16,17}. This suggests that while *GATA2* deregulation plays an important role in leukemogenesis in the *CEBPA*^{MUT} context, *TET2* deficiency may likely contribute to malignancy through additional mechanisms that shall remain the subject of future work. Of clinical interest, we find that *TET2* deficiency renders *Cebpa*^{DM} AML sensitive to 5-AZA and that *TET2*-deficient cells lose their proliferative advantage over *TET2*-proficient cells following 5-AZA treatment. In agreement with *TET2*-dependent *Gata2* expression, ours and previous results




Fig. 7 | *TET2* lesions enhance the aggressiveness of *CEBPA*-mutant AML by rebalancing *GATA2* expression. **a** Model of *Gata2* differential expression as a consequence of (I) elevated *CEBPA* p30 due to the hypermorphic effect of the *CEBPA*^{NT}, (II) *TET2* deficiency and, (III) *CEBPA* deficiency. **b** Schematic illustration of two strategies for *CEBPA*^{DM} AML to rebalance *GATA2* levels by (I) loss-of-function mutations in *TET2* and (II) loss-of-function mutations in one *GATA2* allele. The illustrations were created with BioRender.com.

show that 5-AZA treatment derepresses *Gata2* expression in *TET2*-deficient cells⁴⁴. Intriguingly, *CEBPA*^{CT} mutations have recently been reported to sensitize AML to treatment with hypomethylating agents by disrupting the inhibitory interaction with DNMT3A mediated by the wild-type *CEBPA* bZIP domain⁶⁹. Taken together, this suggests that demethylating agents could be a particularly interesting treatment option in *CEBPA*^{DM}*TET2*^{MUT} patients.

Finally, we note that although our mechanistic data have been acquired in experimental models of complete *TET2* loss, data from AML patients indicates that *TET2* haploinsufficiency is sufficient to rebalance *GATA2* levels. We are also aware of the fact that our experimental models mimic AML in which the *CEBPA* p30 variant constitutes the sole *CEBPA* entity, which is different from the combination of N- and C-terminal mutations that constitutes the bulk of human *CEBPA*^{DM} AML cases. However, since our main findings from the murine *Cebpa*^{p30/p30}/*Cebpa*^{Δ/p30} models are also observed in human *CEBPA*^{DM} AML (including upregulation of *CEBPA* and *GATA2* in leukemic GMPs compared to normal GMPs, as well as rebalancing of *GATA2* expression and worsened outcome by the acquisition of *TET2* lesions), we believe that our observations indicate that a similar disease-relevant *CEBPA*-*TET2* axis is active in human *CEBPA*^{DM} AML.

In conclusion, our results reveal that *GATA2* is a conserved target of the *CEBPA*-*TET2* mutational axis in *CEBPA*^{DM} AML and we propose an intricate mechanism by which elevated *CEBPA* p30 levels mediate recruitment of *TET2* to regulatory regions of the *Gata2* gene to promote its expression. We demonstrate that increased *GATA2* levels are disadvantageous to *CEBPA*^{DM} leukemic cells and that this can be counteracted by *TET2* loss thus providing an explanation for the co-occurrence of *CEBPA* and *TET2* lesions in AML. Finally, increased *Gata2* promoter methylation, inflicted by *TET2* deficiency, can be restored by demethylating 5-AZA treatment, thereby providing entry points for the

development of rational targeted therapies in AML patients with these mutations.

Methods

Patient data

Assessment of mutational status. To evaluate co-occurring mutations in *CEBPA*^{DM} AML cases, data from published studies^{3–8,17} including >40 *CEBPA*^{DM} cases were extracted, and co-occurring mutations were evaluated (Supplemental Table 1). To determine frequencies of target gene mutations between *CEBPA*^{DM} AML cases with *TET2*^{MUT} compared to *TET2* wild-type (*TET2*^{WT}) AML cases, data from published studies^{3–5,7,8,17,51} with specified mutational status including >40 *CEBPA*^{DM} cases or corresponding cohorts were extracted and co-occurring mutations in *TET2*, *GATA2*, *WT1*, *CSF3R*, and *ASXL1* were evaluated (Supplemental Table 2a–e). To examine how the mutational status of *TET2* and *GATA2* were affected by *CEBPA* expression levels in AML, we utilized the publicly available data from the Beat AML cohort (Oregon Health & Science University; OHSU)¹, including 382 cases for which mutation and mRNA expression data were available. The cases were stratified based on *CEBPA* mRNA expression levels (*z*-score ± 1.0 relative to all samples; *CEBPA*^{HIGH} *n* = 45 and *CEBPA*^{LOW} *n* = 61) and frequencies of *CEBPA*, *TET2*, and *GATA2* mutations were determined.

Survival analysis. The clinical data set comprises 298 patients with *CEBPA* mutations (MLL Munchner Leukämie Labor GmbH), of which 152 harbored biallelic *CEBPA* mutations. Out of these 119 had specified *TET2* mutational status and were included in the analyses (*CEBPA*^{DM}*TET2*^{WT} *n* = 84, *CEBPA*^{DM}*TET2*^{MUT} *n* = 35; Supplemental Table 3). All patients gave written informed consent for the use of data for scientific evaluations. The study was approved by the Internal Review Board and by the Bavarian Ethics Committee, the Bavarian State Medical Association (Bayerische Landesärztekammer) with the number 05117. The study adhered to the tenets of the Declaration of Helsinki.

Gene expression. The Beat AML dataset used in this study is available at <http://vizome.org/aml> and comprises 25 patients with *CEBPA* mutations (*CEBPA*^{NT} and/or *CEBPA*^{CT}) for which mutation and mRNA expression data is available. For the gene expression analysis, we excluded patients, which had co-occurring mutation(s) in *WT1* or *IDH1/2* since these have been shown to interfere with *TET2* function^{70–73} as well as two patients with low *CEBPA* variant allele frequency (VAF). Gene expression analysis was conducted on data from 16 *CEBPA*-mutant patients of which 5 have a co-occurring mutation in *TET2* (*TET2*^{MUT}) (Supplemental Table 4). Differential expression analysis was performed with DESeq2⁷⁴ (v. 1.26.0, RRID:SCR_015687) and default parameters. To assess gene expression changes in *CEBPA*^{WT} patients with *TET2*^{MUT} vs *TET2*^{WT}, we included patients with normal karyotype AML from the Beat AML dataset and excluded patients with mutation(s) in *WT1* or *IDH1/2* (*CEBPA*^{WT}*TET2*^{MUT} *n* = 34 and *CEBPA*^{WT}*TET2*^{WT} *n* = 167). To analyze *CEBPA* and *GATA2* expression levels in *CEBPA*^{WT} vs. *CEBPA*^{NT} AML mRNA expression of the two genes together with mutational and karyotype status data was retrieved from the Beat AML study¹ via cBioPortal^{75,76} (RRID:SCR_014555). We evaluated patients for whom data was available for genomic profiling including mRNA expression, mutations, and karyotype. We included patients with normal karyotype AML and excluded patients with mutation(s) in *WT1* or *IDH1/2* (*CEBPA*^{WT} *n* = 52 and *CEBPA*^{NT} *n* = 15).

In vitro experiments

Competitive CRISPR-targeting. For generation of *Tet2* or *Gata2* mutated clones, *Cebpa*^{p30/p30} (δ) cells³⁷ were electroporated with ribonucleoprotein particles containing recombinant Cas9 nuclease from *Streptococcus pyogenes* (Sp) (#1081058, IDT), tracrRNA (#1075927, IDT) and crRNAs (Alt-R® CRISPR-Cas9 crRNA, IDT) targeting *Tet2* and *Gata2*, respectively. crRNAs were designed using the CHOPCHOP⁷⁷

web tool (chopchop.cbu.uib.no, RRID:SCR_015723) (Supplemental Table 5). crRNA and tracrRNA molecules were complexed at room temperature and assembled with recombinant SpCas9 according to the manufacturer's protocols (IDT). Pools of *Tet2*- or *Gata2*-targeted cells were screened at regular intervals to monitor the outgrowth of subpopulations. The genomic regions that were targeted with CRISPR/Cas9 technology were PCR-amplified, Sanger sequenced, and analyzed with the online tool Tracking of Indels by DEcomposition (TIDE)⁷⁸ for insertions or deletions (indels) in the targeted region. Primers for PCR are provided in Supplemental Table 6.

Gata2 enhancer CRISPR-targeting. sgRNA sequences targeting the *Gata2* distal hematopoietic enhancer (G2DHE) were obtained from the UCSC Genome Browser⁷⁹ (genome.ucsc.edu, RRID:SCR_005780) and targets with a high predicted cleavage (Doench/Fusi 2016 Efficiency > 55)⁸⁰ selected (Supplemental table 5). SpCas9-expressing *Cebpa*^{p30/p30}*Tet2*^{MUT} cells were isolated after lentiviral expression of lenti-Cas9-Blast (#52962 Addgene). *Cebpa*^{p30/p30} and *Cebpa*^{p30/p30}*Tet2*^{MUT} cells were co-transduced with pLenti-hU6-sgG2DHE_A/B-IT-PGK-iRFP and LentiGuide-sgG2DHE_1-6-Puro-IRES-GFP. GFP⁺iRFP670⁺ cells were sorted via fluorescence-activated cell sorting (FACS) and frozen for subsequent analysis.

Cebpa shRNA-knockdown. *Cebpa*^{p30/p30} rtTA3 cells expressing Dox-inducible shRNAs against Renilla luciferase (shRen, control) or *Cebpa* (sh*Cebpa*) were used as previously described¹². *Cebpa* knockdown was induced by the addition of 4-hydroxytamoxifen (4-OHT; 1 μM; #H7904 Sigma-Aldrich) to the cell culture medium to activate shRNA expression (mean *Cebpa* knockdown efficiency > 90% compared to shRen control) and cells were collected for further analysis after 48 h.

In vivo experiments

Experiments were carried out according to protocols approved by the Danish Animal Ethical Committee. Mice were bred and housed locally at the Department of Experimental Medicine at the University of Copenhagen. The mice were housed in a temperature- and humidity-controlled room with a 06:00–18:00 h light cycle and fed a standard chow diet and tap water *ad libitum*. We used *Tet2*^{fl/fl}⁸¹, *Cebpa*^{p30/+}¹³, *Cebpa*^{fl/fl}⁸² and *Mx1-Cre*⁺⁸³ lines to generate inducible *Tet2*-deficient and *Cebpa*-mutant compound lines. The following genotypes were used for experiments: *Cebpa*^{fl/p30}*Tet2*^{+/+}, *Cebpa*^{fl/fl}*Tet2*^{fl/fl}, *Cebpa*^{fl/p30}*Tet2*^{fl/fl}, *Cebpa*^{fl/p30}*Tet2*^{+/+}*Mx1-Cre*⁺, *Cebpa*^{fl/fl}*Tet2*^{fl/fl}*Mx1-Cre*⁺, and *Cebpa*^{fl/p30}*Tet2*^{fl/fl}*Mx1-Cre*⁺. *Cebpa*^{p30/p30} embryos were generated as previously described¹³. We used *iMLL-AF9*⁺⁸⁴, *Cebpa*^{fl/fl}⁸² and *R26-CreER*⁺⁸⁵ lines to generate an *iMLL-AF9*⁺*Cebpa*^{fl/fl}*R26-CreER*⁺ compound line. Primers for genotyping in are provided in Supplemental Table 6.

During the leukemia initiation and propagation experiments described below, the animals were monitored daily and euthanized when they showed sign(s) of sickness e.g., inactivity, hunched posture, white paws, and/or matted or puffed-up fur as well as pain assessed based on the NC3R's mouse grimace scale⁸⁶ or reduced bodyweight (maximal allowed reduction = 15%). The experiments were terminated after 12 months.

Leukemia initiation (Cebpa^{Δ/p30} model). C57BL/6J.SJL congenic recipients (female, 10–12 weeks old) were lethally irradiated (900 cGy) 12–24 h prior to intravenous injection with 1 × 10⁶ bone marrow (BM) cells from individual donor mice. The mice were given Ciprofloxacin (100 mg/l in acidified water; #17850 Sigma-Aldrich) in the drinking water to prevent infections 3 weeks post-irradiation. Recipient mice were allowed to recover for 6 weeks post-transplantation before Cre-LoxP recombination was induced by two intraperitoneal injections of Poly(I)-Poly(C) (300 μg in 200 μl PBS; #27-4732-01 GE Healthcare) with 48 h rest in-between. The day of the first injection was set as time-point zero for the survival study and mice were monitored for leukemia

development and euthanized when moribund. To follow leukemia initiation in the recipients, a subgroup of mice was subjected to blood and BM sampling at 12, 24, and 36-week time-points. BM from moribund mice was collected and frozen (10% DMSO in FBS; #D8418 Sigma-Aldrich, #HYCLSV30160.03 Hyclone) for subsequent FACS and analysis.

Leukemia initiation (Cebpa^{p30/p30} model). C57BL/6J.SJL congenic recipients (female, 10 weeks old) were lethally irradiated (900 cGy) 12–24 h prior to intravenous injection with 0.5–1 × 10⁶ fetal liver cells from E15.5 *Cebpa*^{p30/p30} embryos. The mice were given Ciprofloxacin (100 mg/l in acidified water) in the drinking water to prevent infections 3 weeks post-irradiation. Latency to leukemic initiation was 8–11 months.

Leukemia propagation. C57BL/6J.SJL recipients (female, 10–12 weeks old) were lethally irradiated (900 cGy) 12–24 h prior to being intravenously injected with 2 × 10⁵ thawed live BM cells from moribund donor mice together with 4 × 10⁵ freshly isolated BM cells from C57BL/6J.SJL mice. The day of the injection was set as time-point zero for the survival study and mice were monitored and euthanized when moribund. The mice were given Ciprofloxacin in the drinking water to prevent infections 3 weeks post-irradiation.

Competitive shRNA-knockdown. C57BL/6J.SJL recipients (female, 10–12 weeks old) were sub-lethally irradiated (500 cGy) 12–24 h prior to being intravenously injected with a 1:1 mix of *Cebpa*^{p30/p30} cells¹³ transduced with shRNA targeting *Gata2* (detailed in ShRNA knockdown below) or with control-shRNA⁸⁷. The ratio of *Gata2*- or control-shRNA-GFP⁺ to control-shRNA-YFP⁺ cells was analyzed by flow cytometry four weeks later.

5-azacytidine treatment. C57BL/6J.SJL recipients (female, 10–12 weeks old) were sub-lethally irradiated (500 cGy) 12–24 h prior to being intravenously injected with 1 × 10⁵ thawed live BM cells from moribund secondary recipient mice. The mice were given Ciprofloxacin in the drinking water to prevent infections 3 weeks post-irradiation. The mice received intraperitoneal injections with the demethylating agent 5-azacytidine (2.5 mg/kg/day in saline; #A2385 Sigma-Aldrich) at days 6–10 and 20–24 post-transplantation. The time of the BM cell injection was set as time-point zero for the survival study and mice were monitored and euthanized when moribund. To evaluate the effects of short-term 5-azacytidine treatment, recipient mice were treated at days 13–15 and euthanized 24 h after the last injection. BM was collected for FACS, and sorted cells were frozen for subsequent analysis.

Ex vivo cell culture

Establishment of ex vivo Cebpa^{Δ/p30}Tet2^{+/+} and Cebpa^{Δ/p30}Tet2^{Δ/Δ} lines. Thawed cryo-preserved cells from primary AML were cultured in Lonza X-VivoTM 15 cell medium (#BE02-060Q Thermo Fisher Scientific) supplemented with Bovine Serum Albumin in Iscove's MDM (10%; #09300 StemcellTM Technologies), Penicillin-Streptomycin (1%; #15140122 Gibco), β-mercaptoethanol (0.1 mM; #31350010 Gibco), L-glutamine (2 mM; #25030149 Gibco), and cytokines h-IL-6 (50 ng/ml; #130-093-032 Miltenyi Biotec), m-SCF (50 ng/μl; #250-03 Peprotech), m-IL-3 (10 ng/ml; #213-13 Peprotech), and m-GM-CSF (10 ng/ml; #315-03 Peprotech). Two clones of each genotype (*Cebpa*^{Δ/p30}*Tet2*^{+/+} and *Cebpa*^{Δ/p30}*Tet2*^{Δ/Δ}) continued to expand beyond 40 days and withstood freeze-thawing, and these clones have been used for further experiments.

Vitamin C treatment. Cells were seeded at a density of 2 × 10⁵ cells/ml and the cell culture medium was supplemented with vitamin C (100 μg/ml; L-ascorbic acid, #A8960 Sigma Aldrich). Live cells were

counted using Solution 13 (AO-DAPI; #910-3013 Chemometec) on a NucleoCounter® NC-3000™ and reseeded at 2×10^5 cells/ml every third day. The experiments were run with a total of two biological replicates per genotype (performed on separate days) where each experiment assayed one leukemic line per genotype. Each condition (Vitamin C and vehicle) was performed in technical triplicates for each of the two biological replicates per genotype.

5-azacytidine treatment. Cells were seeded at a density of 2×10^5 cells/ml and medium supplemented with 5-azacytidine (5-AZA; 1 μ g/ml; #A2385 Sigma-Aldrich). Live cells were counted using Solution 13 on a NucleoCounter® NC-3000™ and reseeded at 2×10^5 cells/ml days three and six. 24 hours later, up to 1×10^5 cells were isolated and resuspended in RA1 buffer (NucleoSpin RNA XS, #740902 Macherey-Nagel). The experiments were run with a total of two biological replicates per genotype (performed on separate days) where each experiment assayed one leukemic line per genotype. Each condition (5-AZA and vehicle) was performed in technical triplicates for each of the two biological replicates per genotype.

Establishment of ex vivo iMLL-AF9⁺Cebpa^{fl/fl}R26-CreER⁺ lines. Sorted GMPs from iMLL-AF9⁺Cebpa^{fl/fl}R26CreER⁺ mice, were cultured in MethoCult (M3434; #03434, Stemcell technologies) supplemented with doxycycline (1 μ g/ml; #D9891 Sigma-Aldrich) for three replatings to induce expression of the MLL-fusion protein.

Cebpa knockout. Leukemic iMLL-AF9⁺Cebpa^{fl/fl}R26CreER⁺ cells were cultured in RPMI 1640 medium (#21875034, Gibco) supplemented with FBS (10%), Penicillin-Streptomycin (1%), doxycycline (1 μ g/ml), and cytokines m-IL-3 (6 ng/ml), m-SCF (50 ng/ml), and h-IL-6 (10 ng/ml). After two days, 4-hydroxytamoxifen (4-OHT; 1 μ M; #H7904 Sigma-Aldrich) or vehicle was added to the cell culture medium to activate Cre-LoxP recombination, resulting in a reduction of Cebpa mRNA to $1.7 \pm 0.3\%$ vs. $100 \pm 12.3\%$ in vehicle control. Three days later cells were isolated and either frozen or resuspended in RA1 buffer (NucleoSpin RNA XS, #740902 Macherey-Nagel). The experiments were run with a total of two biological replicates (performed on separate days). Each condition (4-OHT and vehicle) was performed in 2-3 technical triplicates for each of the two biological replicates.

ShRNA knockdown

Cloning of shRNA into pMLS vector. Murine shRNAs targeting *Gata2* (sh*Gata2*) were cloned into MSCV-LTRmir30-SV40-GFP vector. Targeting sequences were identified from the Mission® shRNA library (Supplemental Table 7) and the sense and anti-sense sequences were incorporated with a miR-30-loop to generate a 97-mer target sequence. Oligonucleotides were amplified by PCR using miR30 common primers (Supplemental Table 6), which include restriction sites for *XhoI* and *EcoRI*. The resulting 138-mer PCR amplicons and the vector were digested with *XhoI* and *EcoRI* and products were ligated using T4 DNA Ligase (#15224025 Invitrogen). Bacterial transformation was performed to amplify individual ligation products, and correct inserts were verified by Sanger Sequencing. These, together with vectors containing a control non-targeting sequence (MSCV-LTRmir30-SV40-GFP and MSCV-LTRmir30-SV40-YFP), were used in subsequent transfection/transduction experiments, as previously described^{87,88}.

Transduction of Cebpa^{p30/p30} cells. Retroviral transduction was done as previously described⁸⁷. Briefly, retroviral supernatants were generated by transfection of Phoenix-Eco cells (RRID:CVCL_H717). For transduction, retroviral supernatant was added onto retronectin-coated (1:25; #T100B TaKaRa) non-tissue culture treated plates and centrifuged at 2000 \times g for 60 min at 4 °C. After aspiration of the supernatant, Cebpa^{p30/p30} cells were seeded at a density of $0.5-1 \times 10^5$

cells/cm². The transduction was repeated the following day, and the cells were cultured for 24 h prior to FACS sorting of transduced (GFP⁺/YFP⁺) cells on a BD FACSAria™ III (BD Bioscience). The efficiency of shRNA-mediated gene expression knockdown was assessed with qPCR and cells were used for transplantation and assessment of their competitiveness in vivo.

Immuno-staining

Flow cytometry. To analyze the composition of either freshly isolated or thawed cryopreserved BM and blood, cells were stained with fluorescently labelled antibodies. For blood analysis, 50 μ l blood was collected from the facial vein and erythrocytes were lysed with lysing buffer (BD Pharm Lyse™, #555899 BD Bioscience). For BM analysis, cells were collected by crushing tibia, femur, and ilium and filtered through a 50 μ m filcon cup (#340630 BD Bioscience). Blood or BM cells were washed in PBS with 3% FBS and stained with fluorescently labelled antibodies for 30 min at 4 °C (Supplemental Table 8). For cryopreserved cells, the cells were counterstained with DAPI (1:10000; #D3571 Invitrogen) to separate out dead cells. Fluorochrome-minus-one was used as controls. Flow cytometry data was obtained using a BD FACSAria™ III or a BD LSR II™ (BD Bioscience) and analyzed using FlowJo software (v9, RRID:SCR_008520).

For downstream transcriptional and epigenetic analyses, live donor-derived non-lymphoid and non-erythroid cells (DAPI⁺CD45.2⁺CD3⁺B220⁺Ter119⁻) were sorted using a BD FACSAria™ III, spun down and cell pellets were either snap-frozen or resuspended in RLT buffer (RNeasy Mini Kit, #74104 Qiagen).

For ex vivo cell culture of iMLL-AF9⁺Cebpa^{fl/fl}R26-CreER⁺ cells, c-kit⁺ BM cells were enriched by magnetic sorting (mouse CD117 MicroBeads; #130-091-224, Miltenyi Biotec) and granulocyte/monocyte progenitors (GMPs; Lin⁻C-kit⁺Scal⁺CD41⁺FcgRII⁺) were sorted using a BD FACSAria™ III.

Immunohistochemistry. To evaluate the proliferative status of leukemia cells, cells from BM of moribund mice were spun on glass slides, air-dried, and fixed with methanol (#VWRC20846.292 VWR). After blocking of endogenous peroxidase activity with hydrogen peroxide (1%), slides were stained overnight at 4 °C with anti-Ki67 antibody (1:50; Clone SP6, RRID:AB_302459, #ab16667 Abcam) in antibody diluent (S3022 Dako). To visualize the primary antibody, EnVision HRP Rabbit (K4003 Dako) together with Vina Green™ Chromogen Kit (BRR807 Biocare Medical) was utilized according to manufacturer's instructions. The cells were counterstained with Mayer Hematoxylin (#51275 Sigma-Aldrich), dehydrated and coverslips mounted with Entellan (#107960 Sigma-Aldrich). Images were captured using a Leica microscope at 20X magnification and Ki67⁺ cells were quantified out of one hundred cells.

Western blotting. Western blotting for TET2 was performed according to standard laboratory protocols, using the following antibodies: anti-TET2 (1:100, Clone C-7, RRID:AB_2924805, #sc-398535 Santa Cruz) and anti-HSC70 (1:10000, Clone B-6, RRID:AB_627761, #sc-7298 Santa Cruz).

Quantitative PCR

RNA from sorted blasts or ex vivo-cultured cells was isolated using NucleoSpin RNA XS kit (#740902 Macherey-Nagel) or RNeasy Mini Kit (#74104 Qiagen) according to the manufacturers' instructions and converted to cDNA using ProtoScript First Strand cDNA Synthesis Kit (#E6300 New England BioLabs). Quantitative PCR (qPCR) to assess knockdown efficiency was run using TaqMan Fast Advanced Master Mix (#4444556 Applied Biosystems) and TaqMan assay for *Gata2* (Mm00492301_m1 FAM-MGB), in duplex with housekeeping gene *18S* (Hs99999901_s1 VIC-MGB-PL). TaqMan assay for *Ki67* (Mm01278617_m1 FAM-MGB) was used to assess the expression of the

proliferation marker. qPCR to evaluate mRNA levels of total *Gata2*, *variant 1 (V1)* and *variant 2 (V2)*, respectively, was run in duplex using LightCycler 480 SYBR Green I Master (#04887352001 Roche) with primers for *Gata2* and housekeeping gene *Actb* and *Gapdh*⁴¹ (Supplemental Table 6). Gene expression was calculated with the $2^{-\Delta\Delta C_t}$ method.

RNA from *Cebpa*^{p30/p30} cell lines was isolated using RNeasy Plus Mini Kit (#74134 Qiagen) according to the manufacturer's instructions and converted to cDNA with RevertAid First Strand cDNA Synthesis Kit (#K1622 Thermo Scientific). qPCR was run using SsoAdvanced Univ SYBR Gm Suprmix (#1725271, Bio-Rad Laboratories Ges.m.b.H.) and primers for *Gata2* and *Gapdh* (Supplemental Table 6).

Bisulfite PCR

DNA was isolated using DNeasy Blood and tissue kit (#69504 Qiagen) and the DNA was bisulfite converted using EZ-DNA Methylation Gold Kit (#D5005 Zymo Research), both according to the manufacturer's instructions. PCR was run using Pfu Turbo Cx Hotstart DNA polymerase (#600410 Agilent) with primers targeting a part of the CpG island in the *Gata2* V2 promoter region (Supplemental table 6). After verification of their correct size, PCR products were cloned using Zero Blunt Topo PCR Cloning kit (#450245 Invitrogen), and single colonies were picked and amplified. Plasmid DNA was isolated using NucleoSpin Plasmid EasyPure (#740727.250 Macherey-Nagel), the correct insert size was verified after cleavage with restriction enzyme EcoRI (#R0101 New England Biolabs) and sent for Sanger sequencing using the M13 primer provided with the cloning kit.

Chromatin immunoprecipitation (ChIP)-qPCR

ChIP for CEBPA was performed as previously described³⁷ using an anti-CEBPA antibody (1:60, C-18, RRID:AB_2078046, #sc-9314, Santa Cruz Biotechnology). ChIP for TET2 was performed using an anti-TET2 antibody (1:50; clone D6C7K, RRID:AB_2799102, #36449, Cell Signaling Technology), as previously described³⁷, including a 30-minute incubation with 2 mM disuccinimidyl glutarate (DSG; #20593 Thermo Scientific) before the 1% formaldehyde crosslinking step. The sequences used for qPCR are listed in Supplemental table 6.

High-throughput sequencing and bioinformatic analyses

RNA-sequencing (RNA-seq) of cell line models. RNA was isolated from 1×10^6 cells using RNeasy Plus Mini Kit (#74134 Qiagen) according to the manufacturer's instructions and quality was assessed on a Bioanalyzer 2100 G2939A (Agilent). 1 μ g of RNA was used to generate sequencing libraries using QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) for Illumina, 96 preps (#015.96, Lexogen) and the PCR Add-on Kit for Illumina, 96 rxn (#020.96, Lexogen). The libraries were quantified on a Bioanalyzer 2100 G2939 (Agilent) and pooled in equimolar amounts. Multiplexed libraries were sequenced on a HiSeq4A (Illumina).

RNA-seq of leukemic cells from in vivo models. RNA was isolated from 5×10^5 sorted cells using RNeasy Mini Kit (#74104 Qiagen) according to the manufacturer's instructions and quality was assessed by RNA 6000 Pico Kit (#5067-1513 Agilent) on a Bioanalyzer 2100 (Agilent). 200 ng RNA was used to generate sequencing libraries using TruSeq RNA Library Prep Kit v2 (#RS-122-2001 Illumina). The libraries were quantified using Qubit dsDNA BR Assay Kit (#32853 Thermo Fisher Scientific) and DNA 1000 Kit (#5067-1504 Agilent) and pooled in equimolar amounts. Multiplexed libraries were sequenced on a NextSeq 500 (Illumina) using NextSeq 500 High Output v2 Kit (75 cycles; #FC-404-2005 Illumina).

Bioinformatics analyses of RNA-seq data. RNA-seq analysis for in vitro *Cebpa*^{p30/p30} cells was performed as previously described^{12,37}. Quality check was done with FastQC⁸⁹ (v. 0.11.4, RRID:SCR_014583) and

preprocessing with PRINSEQ-lite⁹⁰ (v. 0.20.4; RRID:SCR_005454), using parameters: `-min_len 30 -min_qual_mean 30 -ns_max_n 5 -trim_tail_right 8 -trim_tail_left 8 -trim_qual_right 30 -trim_qual_left 30 -trim_qual_window 5`. The remaining reads were aligned against the mouse reference genome (mm10) with BWA⁹¹ (v. 0.7.15; RRID:SCR_010910). RNA-seq analysis for in vivo *Cebpa*^{p30} cells was performed as follows. RNA-seq reads were processed with the bcbio RNA-seq pipeline⁹² (<https://github.com/bcbio/bcbio-nextgen>, RRID:SCR_004316) and the bcbioRNASeq R package (<https://github.com/hbc/bcbioRNASeq>). In brief, transcript abundance estimates were obtained using Salmon⁹³ (v. 0.12.0, RRID:SCR_017036) against reference transcriptome GRCm38/mm10 ENSEMBL release 94, summarized to gene level and imported into R using tximport⁹⁴ (v. 1.10.1, RRID:SCR_016752) (using setting `countsFromAbundance = "lengthScaledTPM"`). Differential gene expression analysis between the *Cebpa*^{p30}*Tet2*^{+/+} and *Cebpa*^{p30}*Tet2*^{Δ/Δ} genotype was performed using DESeq2 with standard parameters⁷⁴ (v. 1.22.2, RRID:SCR_015687) excluding lowly expressed genes (<10 sum normalized counts across all samples) and running with `alpha = 0.05`.

Gene expression levels between primary *Cebpa*^{p30}*Tet2*^{+/+} and established *Cebpa*^{p30/p30} leukemias were compared using edgeR (v. 3.32.1, RRID:SCR_012802).

Gene set enrichment analysis (GSEA). GSEA was performed using the GSEA software^{95,96} (v. 4.1.0, RRID:SCR_003199) and the Molecular Signatures Database (RRID:SCR_016863).

Assay for transposase-accessible chromatin-sequencing (ATAC-seq). ATAC-seq was performed as previously described¹².

Bioinformatics analyses of ATAC-seq data. Analysis of ATAC-seq was performed as previously described¹². HOMER⁹⁷ (v. 4.11, RRID:SCR_010881) was used to identify motifs enriched in the ATAC peaks.

Bisulfite whole genome sequencing (WGBS). DNA was isolated from 1×10^6 sorted cells using DNeasy Blood and tissue kit (#69504 Qiagen) according to the manufacturer's instructions. Bisulfite conversion of DNA was done according to manufacturers' instructions using EZ-DNA Methylation Gold Kit (#D5005 Zymo Research). Quality of bisulfite treated DNA was assessed by RNA 6000 Pico Kit (#5067-1513 Agilent) on a Bioanalyzer 2100. Libraries of bisulfite-converted DNA were prepared using Pico Methyl-Seq Library Prep Kit (#D5455 Zymo Research) according to manufacturer's instructions and the final concentration and quality of the libraries was assessed using Qubit dsDNA HS Assay Kit (#Q32854 Thermo Fisher Scientific) and High Sensitivity DNA Analysis Kit (#5067-4626 Agilent) on a Bioanalyzer. Duplexed libraries were sequenced on a NextSeq 500 (Illumina) using NextSeq 500 High Output v2 Kit (75 cycles).

Bioinformatics analyses of WGBS data. Reads were trimmed and filtered using Trim Galore⁹⁸ (v. 0.4.3, RRID:SCR_011847) with default parameters, and quality was assessed before and after using FastQC⁸⁹ (v. 0.11.7). Trimmed reads were aligned to the mouse genome assembly GRCm38 (mm10) using Bismark⁹⁹ (v. 0.19.1, RRID:SCR_005604) with option `-non_directional` (other parameter left at default values; this used Bowtie 2¹⁰⁰ (v. 2.2.8 RRID:SCR_016368) with `-q --score-min L,0,-0.2 --ignorequals`). After deduplication of alignments (using `deduplicate_bismark`), the methylation information for individual cytosines was extracted using `bismark_methylation_extractor` (`-cytosine_report --comprehensive --gzip`). To quantify DNA methylation of gene bodies and promoters (1000 bp up-and downstream of transcription start sites), we used the weighted methylation level (i.e., summarizing over all CpG positions in the given region, the number of reads supporting methylated cytosine divided by the number of all reads covering these positions). Plots of average methylation levels

across extended gene bodies were generated using deepTools¹⁰¹ (v.3.1.3, RRID:SCR_016366) computeMatrix (scale-regions -m 4000 -a 1000 -b 1000 --unscaled5prime 1000 --unscaled3prime 1000) and plotProfile, for which Bismark-generated bedGraph files were converted to BigWig format (using UCSC's bedGraphToBigWig¹⁰² (v. 4)).

Bioinformatic analyses of chromatin immunoprecipitation-sequencing (ChIP-seq). ChIP-seq data from in vitro *Cebpa*^{p30/p30} cells was processed as described¹². ChIP-seq data from in vivo *Cebpa*^{p30/p30} cells was processed as follows; raw reads derived from CEBPA (*Cebpa*^{+/+} and *Cebpa*^{p30/p30}) ChIP-seq experiments were mapped to mouse (mm10) genome assembly using Bowtie 2¹⁰⁰ (v. 2.3.4.3). We used uniquely mapped and PCR duplicates (exact copies) collapsed as one read and extended to their fragment length by determining the read extension size using MACS2¹⁰³ (v. 2.1.0.20151222; predicted parameter, RRID:SCR_013291). Raw read counts were normalized to TPM using deepTools¹⁰¹ (v. 3.3.1; bamCoverage). Raw read counts (CEBPA binding levels) mapping to *Gata2* promoter and enhancer regions were computed using bedtools¹⁰⁴ (v. 2.30.0; multicov, RRID:SCR_006646), and the differences in CEBPA binding between *Cebpa*^{+/+} and *Cebpa*^{p30/p30} conditions were computed using DESeq2⁷⁴ (v. 1.30.1). Sequencing reads derived from TET2 ChIP-seq experiment were preprocessed with PRINSEQ-lite⁹⁰ (v. 0.20.4; RRID:SCR_005454) and the remaining reads were mapped to the mouse reference genome sequence (mm10) using BWA⁹¹ (v. 0.7.17-r1188, RRID:SCR_010910). The resulting alignments were processed with samtools¹⁰⁵ (v. 1.13; RRID:SCR_002105) and peak calling was done with MACS2¹⁰³ (v. 2.1.0.20140616; RRID:SCR_013291). Aligned read counts were normalized to RPKM using the bamCoverage function from deepTools¹⁰¹ (v. 3.5.1; RRID:SCR_016366).

Statistics

Data were analyzed for significance using parametric tests, with prior log-transformation if necessary to achieve normal distribution. Normality was evaluated by Shapiro–Wilk test. Two-group analyses were done using an unpaired two-tailed *t*-test. Multiple-group analyses were done with one-way-ANOVA followed by multiple comparisons correction using Dunnett when comparing to a reference group, or two-way-ANOVA followed by multiple comparisons correction using Šidák test when comparing two independent factors across four groups. Data sets that did not pass normality tests were analyzed by Kruskal–Wallis test followed by multiple comparisons correction using Dunn's test. Survival curves were analyzed using Mantel–Cox Log-rank test. To compare distributions Wilson/Brown binomial test was used. To compare a median against a hypothetical median Wilcoxon signed-rank test was used. *p*-values < 0.05 were considered statistically significant. Data was analyzed using GraphPad Prism (v. 9, RRID:SCR_002798). Data is shown as mean ± SEM unless otherwise stated.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The data generated in this study is publicly available in Gene Expression Omnibus (GEO) under accession numbers GSE214224 (RNA-seq, ATAC-seq, and TET2 ChIP-seq in vitro) and GSE213864 (RNA-seq and WGBS in vivo), and within the article and its supplementary files. The following other publicly available data was used in this study: CEBPA and H3K27Ac ChIP-seq from myeloid progenitor cell model for p30-driven AML¹² is available under GSE158727. CEBPA ChIP from mouse *Cebpa*^{+/+} or *Cebpa*^{p30/p30} GMPs¹¹ is available under GSE118963. RNA-seq data from *Cebpa*^{p30/p30} AML^{11,34} are available under GSE118963 and GSE141477. Patient data analyzed in this study were from the Beat AML study (accessed through cBioPortal⁷⁵⁷⁶ [<https://www.cbioportal.org/>]

or Vizome¹ [<http://www.vizome.org/>]) or from published cohort studies (Supplemental tables 1, 2a–e). Source data are provided with this paper.

References

1. Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. *Nature* **562**, 526–531 (2018).
2. Ohlsson, E., Schuster, M. B., Hasemann, M. & Porse, B. T. The multifaceted functions of C/EBPalpha in normal and malignant haematopoiesis. *Leukemia* **30**, 767–775 (2016).
3. Fasan, A. et al. The role of different genetic subtypes of CEBPA mutated AML. *Leukemia* **28**, 794–803 (2014).
4. Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. *N. Engl. J. Med.* **374**, 2209–2221 (2016).
5. Ahn, J. S. et al. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. *Ann. Hematol.* **95**, 301–310 (2016).
6. Su, L. et al. Mutational spectrum of acute myeloid leukemia patients with double CEBPA mutations based on next-generation sequencing and its prognostic significance. *Oncotarget* **9**, 24970–24979 (2018).
7. Zhang, Y. et al. Companion gene mutations and their clinical significance in AML with double mutant CEBPA. *Cancer Gene Ther.* <https://doi.org/10.1038/s41417-019-0133-7> (2019).
8. Taube, F. et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. *Blood* **139**, 87–103 (2022).
9. Wilhelmson, A. S. & Porse, B. T. CCAAT enhancer binding protein alpha (CEBPA) biallelic acute myeloid leukaemia: cooperating lesions, molecular mechanisms and clinical relevance. *Br. J. Haematol.* **190**, 495–507 (2020).
10. Leroy, H. et al. CEBPA point mutations in hematological malignancies. *Leukemia* **19**, 329–334 (2005).
11. Jakobsen, J. S. et al. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. *Sci. Adv.* **5**, eaaw4304 (2019).
12. Heyes, E. et al. Identification of gene targets of mutant C/EBPalpha reveals a critical role for MS12 in CEBPA-mutated AML. *Leukemia* **35**, 2526–2538 (2021).
13. Kirstetter, P. et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. *Cancer Cell* **13**, 299–310 (2008).
14. Di Genua, C. et al. C/EBPalpha and GATA-2 mutations induce bilineage acute erythroid leukemia through transformation of a neomorphic neutrophil-erythroid progenitor. *Cancer Cell* **37**, 690–704.e698 (2020).
15. Braun, T. P. et al. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia. *Nat. Commun.* **10**, 5455 (2019).
16. Grossmann, V. et al. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76.8% of cases with TET2 and GATA2 alterations impacting prognosis. *Br. J. Haematol.* **161**, 649–658 (2013).
17. Konstandin, N. P. et al. Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA. *Blood Adv.* **2**, 2724–2731 (2018).
18. Kunimoto, H. & Nakajima, H. TET2: A cornerstone in normal and malignant hematopoiesis. *Cancer Sci* **112**, 31–40 (2021).
19. Man, N. et al. p300 suppresses the transition of myelodysplastic syndromes to acute myeloid leukemia. *JCI Insight* **6**, <https://doi.org/10.1172/jci.insight.138478> (2021).
20. Reckzeh, K. et al. TET2 deficiency cooperates with CBFb-MYH11 to induce acute myeloid leukaemia and represents an early

- leukaemogenic event. *Br. J. Haematol.* <https://doi.org/10.1111/bjh.18027> (2022).
21. Morinishi, L., Kochanowski, K., Levine, R. L., Wu, L. F. & Altschuler, S. J. Loss of TET2 affects proliferation and drug sensitivity through altered dynamics of cell-state transitions. *Cell Syst* **11**, 86–94.e85 (2020).
 22. An, J. et al. Acute loss of TET function results in aggressive myeloid cancer in mice. *Nat. Commun.* **6**, 10071 (2015).
 23. Li, R. et al. TET2 loss dysregulates the behavior of bone marrow mesenchymal stromal cells and accelerates tet2(-/-)-driven myeloid malignancy progression. *Stem Cell Reports* **10**, 166–179 (2018).
 24. Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. *Nature* **557**, 580–584 (2018).
 25. Weissmann, S. et al. Landscape of TET2 mutations in acute myeloid leukemia. *Leukemia* **26**, 934–942 (2012).
 26. Rasmussen, K. D. et al. TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells. *Genome Res.* **29**, 564–575 (2019).
 27. Jones, P. A. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat. Rev. Genet.* **13**, 484–492 (2012).
 28. Ito, K. et al. Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis. *Cell Rep.* **28**, 2480–2490.e2484 (2019).
 29. Lim, K. C. et al. Conditional Gata2 inactivation results in HSC loss and lymphatic mispatterning. *J. Clin. Invest.* **122**, 3705–3717 (2012).
 30. Koyunlar, C. & de Pater, E. From Basic Biology to Patient Mutational Spectra of GATA2 Haploinsufficiencies: What Are the Mechanisms, Hurdles, and Prospects of Genome Editing for Treatment. *Front. Genome Ed.* **2**, 602182 (2020).
 31. Greif, P. A. et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. *Blood* **120**, 395–403 (2012).
 32. Hou, H. A. et al. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution. *Ann. Hematol.* **94**, 211–221 (2015).
 33. Tien, F. M. et al. GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia. *Blood Cancer J.* **8**, 87 (2018).
 34. Trempenau, M. L. et al. The histone demethylase KDM5C functions as a tumor suppressor in AML by repression of bivalently marked immature genes. *Leukemia* **37**, 593–605 (2023).
 35. Li, H. S. et al. Loss of c-Kit and bone marrow failure upon conditional removal of the GATA-2 C-terminal zinc finger domain in adult mice. *Eur. J. Haematol.* **97**, 261–270 (2016).
 36. Menendez-Gonzalez, J. B. et al. Gata2 as a crucial regulator of stem cells in adult hematopoiesis and acute myeloid leukemia. *Stem Cell Reports* **13**, 291–306 (2019).
 37. Schmidt, L. et al. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. *Leukemia* **33**, 1608–1619 (2019).
 38. Pundhir, S. et al. Enhancer and transcription factor dynamics during myeloid differentiation reveal an early differentiation block in cebpa null progenitors. *Cell Rep.* **23**, 2744–2757 (2018).
 39. Johnson, K. D., Soukup, A. A. & Bresnick, E. H. GATA2 deficiency elevates interferon regulatory factor-8 to subvert a progenitor cell differentiation program. *Blood Adv* **6**, 1464–1473 (2022).
 40. Minegishi, N. et al. Alternative promoters regulate transcription of the mouse GATA-2 gene. *J Biol Chem* **273**, 3625–3634 (1998).
 41. Snow, J. W. et al. A single cis element maintains repression of the key developmental regulator Gata2. *PLoS Genet* **6**, e1001103 (2010).
 42. Ohlsson, E. et al. Initiation of MLL-rearranged AML is dependent on C/EBPalpha. *J Exp Med.* **211**, 5–13 (2014).
 43. Shih, A. H. et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. *Cancer Cell* **27**, 502–515 (2015).
 44. Duy, C. et al. Rational targeting of cooperating layers of the epigenome yields enhanced therapeutic efficacy against AML. *Cancer Discov* **9**, 872–889 (2019).
 45. Christen, F. et al. Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. *Leukemia* <https://doi.org/10.1038/s41375-021-01469-x> (2021).
 46. Rodrigues, N. P. et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. *Blood* **106**, 477–484 (2005).
 47. Miharada, N., Rydstrom, A., Rak, J. & Larsson, J. Uncoupling key determinants of hematopoietic stem cell engraftment through cell-specific and temporally controlled recipient conditioning. *Stem Cell Reports* **16**, 1705–1717 (2021).
 48. Thoms, J. A. I. et al. Disruption of a GATA2-TAL1-ERG regulatory circuit promotes erythroid transition in healthy and leukemic stem cells. *Blood* **138**, 1441–1455 (2021).
 49. Fasan, A. et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. *Leukemia* **27**, 482–485 (2013).
 50. Celton, M. et al. Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia. *Leukemia* **28**, 1617–1626 (2014).
 51. Metzeler, K. H. et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. *Blood* **128**, 686–698 (2016).
 52. Al Seraihi, A. F. et al. GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML. *Leukemia* **32**, 2502–2507 (2018).
 53. Mulet-Lazaro, R. et al. Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double mutant AML. *Blood* <https://doi.org/10.1182/blood.2020009244> (2021).
 54. You, X. et al. Gata2 -77 enhancer regulates adult hematopoietic stem cell survival. *Leukemia* **35**, 901–905 (2021).
 55. Yamazaki, H. et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. *Cancer Cell* **25**, 415–427 (2014).
 56. Groschel, S. et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. *Cell* **157**, 369–381 (2014).
 57. Yamaoka, A. et al. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis. *Blood Adv* **4**, 1722–1736 (2020).
 58. Kiehlmeier, S. et al. Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia. *Leukemia* **35**, 3127–3138 (2021).
 59. Lugthart, S. et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J. Clin. Oncol.* **28**, 3890–3898 (2010).
 60. Groschel, S. et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. *J. Clin. Oncol.* **28**, 2101–2107 (2010).
 61. Groschel, S. et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. *Blood* **125**, 133–139 (2015).
 62. Sardina, J. L. et al. Transcription Factors Drive Tet2-Mediated Enhancer Demethylation to Reprogram Cell Fate. *Cell Stem Cell* **23**, 727–741.e729 (2018).

63. Ramberger, E. et al. PRISMA and BioID disclose motifs-based interactome of the intrinsically disordered transcription factor C/EBPalpha. *iScience* **24**, 102686 (2021).
64. Mann, I. K. et al. CG methylated microarrays identify a novel methylated sequence bound by the CEBPB|ATF4 heterodimer that is active in vivo. *Genome Res* **23**, 988–997 (2013).
65. Suzuki, T. et al. A screening system to identify transcription factors that induce binding site-directed DNA demethylation. *Epigenetics Chromatin* **10**, 60 (2017).
66. Kallin, E. M. et al. Tet2 facilitates the derepression of myeloid target genes during CEBPalpha-induced transdifferentiation of pre-B cells. *Mol. Cell* **48**, 266–276 (2012).
67. Tulstrup, M. et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. *Nat. Commun.* **12**, 6061 (2021).
68. Figueroa, M. E. et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. *Blood* **113**, 2795–2804 (2009).
69. Chen, X. et al. Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity. *Sci. Adv.* **8**, eabl5220 (2022).
70. Figueroa, M. E. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. *Cancer Cell* **18**, 553–567 (2010).
71. Rampal, R. et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. *Cell Rep.* **9**, 1841–1855 (2014).
72. Wang, Y. et al. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. *Mol. Cell* **57**, 662–673 (2015).
73. Wilson, E. R. et al. Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. *Leukemia* **36**, 935–945 (2022).
74. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
75. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404 (2012).
76. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal* **6**, pl1 (2013).
77. Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. *Nucleic Acids Res.* **47**, W171–W174 (2019).
78. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res.* **42**, e168 (2014).
79. Lee, B. T. et al. The UCSC Genome Browser database: 2022 update. *Nucleic Acids Res.* **50**, D1115–D1122 (2022).
80. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016).
81. Quivoron, C. et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell* **20**, 25–38 (2011).
82. Lee, Y. H., Sauer, B., Johnson, P. F. & Gonzalez, F. J. Disruption of the *c/ebp alpha* gene in adult mouse liver. *Mol Cell Biol* **17**, 6014–6022 (1997).
83. de Boer, J. et al. Transgenic mice with hematopoietic and lymphoid specific expression of Cre. *Eur. J. Immunol.* **33**, 314–325 (2003).
84. Stavropoulou, V. et al. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome. *Cancer Cell* **30**, 43–58 (2016).
85. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. *Nature* **445**, 661–665 (2007).
86. Langford, D. J. et al. Coding of facial expressions of pain in the laboratory mouse. *Nat. Methods* **7**, 447–449 (2010).
87. Ge, Y. et al. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia. *Nat. Commun.* **10**, 172 (2019).
88. Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. *Nat. Genet.* **37**, 1289–1295 (2005).
89. Andrews, S. FastQC: A Quality Control Tool for High Throughput Sequence Data [Online]. Available online at: <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/> (2010).
90. Schmieder, R. & Edwards, R. Quality control and preprocessing of metagenomic datasets. *Bioinformatics* **27**, 863–864 (2011).
91. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
92. Steinbaugh, M. bcBioRNASeq: R package for bcBio RNA-seq analysis [version 2; peer review: 1 approved, 1 approved with reservations]. *F1000Res* **6**, 1976 (2018).
93. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
94. Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. *F1000Res* **4**, 1521 (2015).
95. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl Acad. Sci. USA* **102**, 15545–15550 (2005).
96. Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003).
97. Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010).
98. Krueger, F. Trim galore. A wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files [Online]. Available online at: http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/ (2015).
99. Krueger, F. & Andrews, S. R. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. *Bioinformatics* **27**, 1571–1572 (2011).
100. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
101. Ramirez, F., Dundar, F., Diehl, S., Gruning, B. A. & Manke, T. deepTools: a flexible platform for exploring deep-sequencing data. *Nucleic Acids Res.* **42**, W187–191, (2014).
102. Kent, W. J., Zweig, A. S., Barber, G., Hinrichs, A. S. & Karolchik, D. BigWig and BigBed: enabling browsing of large distributed datasets. *Bioinformatics* **26**, 2204–2207 (2010).
103. Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008).
104. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
105. Li, H. et al. The sequence alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–2079 (2009).

Acknowledgements

Work in the Porse lab was supported by grants from the Copenhagen University Hospital, the Capital Region of Copenhagen, the Independent Research Fund Denmark (9039-00189B) and through a center grant from the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; Grant Number NNF17CC0027852). This work has been performed in the context of the Danish Research Center for Precision Medicine in Blood Cancers funded by the Danish Cancer Society (R223-A13071) and Greater Copenhagen Health Science Partners. Work in the Grebien lab was supported by the European Union's Horizon 2020 research and innovation program (European Research

Council grant agreement No 636855 and Austrian Science Fund (FWF), grants no. TAI-490 and P35628. Work in the Schoof lab was supported by a grant from the Independent Research Fund Denmark (case no. 2067-00053B). ASW was supported by grants from The Lundbeck Foundation (R303-2018-2868) and The Swedish Research Council (2015-00517). EH was supported by a grant from Forschungsförderung from the Fellingner Krebsforschungsverein. We thank members of the Grebien and Porse laboratories for their discussions. We thank Anna Fossum for her excellent research assistance.

Author contributions

E.H., A.S.W., G.M., M.B.S., E.R., T.D.A., A.K.F., C.G., J.W., and E.M.S. performed experiments. E.H., A.S.W., A.W., T.E., M.B.S., S.P., and E.M.S. analyzed data. E.H., A.S.W., F.G., and B.T.P. designed experiments. J.F. contributed essential material. M.M. and T.H. provided clinical data. E.H., A.S.W., F.G., and B.T.P. drafted the manuscript. All authors have proof-read and approved the final version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41467-023-41927-x>.

Correspondence and requests for materials should be addressed to Florian Grebien or Bo T. Porse.

Peer review information *Nature Communications* thanks Ross Levine, Cihangir Duy and Cristina Pina for their contribution to the peer review of this work. A peer review file is available.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023